Allosteric activation of T cell antigen receptor signaling by quaternary structure relaxation

Highlights

- Mutations in TCRβ and CD3ζ TMRs that reduce their interaction augment signaling
- pMHC and anti-CD3 binding to TCR-CD3 induce similar quaternary structure relaxation
- Soluble monovalent pMHC alone signals and reduces TCRαβ cohesion with CD3ζ
- Allosteric changes in TCR-CD3 dynamics instigate T cell activation

In brief

T cell antigen receptor is central in adaptive immunity; however, the mechanism that couples ligand binding and intracellular signaling is still controversial. Here, Lanz et al. have taken an interdisciplinary approach demonstrating that binding of soluble monovalent pMHC to TCR-CD3 allosterically reduces TCRαβ cohesion with CD3ζ and initiates signal transduction.
Allosteric activation of T cell antigen receptor signaling by quaternary structure relaxation

Anna-Lisa Lanz, 1,6,9 Giulia Masi, 1,8,10 Nicla Porciello, 1,8 André Cohnen, 1,8,11 Deborah Cipria, 1 Dheeraj Prakaash, 2 Stefán Bálint, 3 Roberto Raggiaschi, 1 Donatella Galgano, 1,12 David K. Cole, 4,5 Marco Lepore, 6 Omer Dushek, 6 Michael L. Dustin, 6 Mark S.P. Sansom, 2,7,13 Antreas C. Kalli, 2,7,13 and Oreste Acuto 1,13

1 T-cell signalling laboratory, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK
2 Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, UK
3 Kennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK
4 Division Infection & Immunity, Cardiff University, Cardiff CF14 4XN, UK
5 Immunocore Ltd., Abingdon OX14 4RY, UK
6 Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK
7 Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK
8 These authors contributed equally
9 Present address: Department of Pediatrics, Ludwigs-Maximilians Universität, Munich, Germany
10 Present address: Enara Bio, Oxford OX4 4GA, UK
11 Present address: Bayer AG, Mullerstrasse 178, 13353 Berlin, Germany
12 Present address: Department of Medicine, Karolinska Institutet, S-14186 Stockholm, Sweden
13 Lead contact
*Correspondence: mark.sansom@bioch.ox.ac.uk (M.S.P.S.), a.kalli@leeds.ac.uk (A.C.K.), oreste.acuto@path.ox.ac.uk (O.A.)

https://doi.org/10.1016/j.celrep.2021.109375

SUMMARY

The mechanism of T cell antigen receptor (TCR-CD3) signaling remains elusive. Here, we identify mutations in the transmembrane region of TCRβ or CD3ζ that augment peptide-major histocompatibility complex (pMHC)-induced signaling not explicable by enhanced ligand binding, lateral diffusion, clustering, or co-receptor function. Using a biochemical assay and molecular dynamics simulation, we demonstrate that the gain-of-function mutations loosen the interaction between TCRαβ and CD3ζ. Similar to the activating mutations, pMHC binding reduces TCRαβ cohesion with CD3ζ. This event occurs prior to CD3ζ phosphorylation and at 0°C. Moreover, we demonstrate that soluble monovalent pMHC alone induces signaling and reduces TCRαβ cohesion with CD3ζ in membrane-bound or solubilised TCR-CD3. Our data provide compelling evidence that pMHC binding suffices to activate allosteric changes propagating from TCRαβ to the CD3 subunits, reconfiguring interchain transmembrane region interactions. These dynamic modifications could change the arrangement of TCR-CD3 boundary lipids to license CD3ζ phosphorylation and initiate signal propagation.

INTRODUCTION

T cell antigen receptor (TCR-CD3) signaling drives thymocyte maturation and T cell responses upon recognition of highly polymorphic major histocompatibility complex (MHC) proteins presenting myriad of short peptides (p) that originated from the degradation of self and foreign proteins (Stritesky et al., 2012). Despite high physical and chemical diversity in binding interfaces, TCR-CD3 ensures responses of exceptional specificity and sensitivity (Davis et al., 2007), with weak affinity (0.1–100 μM) and short half-life (t½) (<0.5 to several seconds) (Aleksic et al., 2012; Cole et al., 2007; Stone et al., 2009). To accomplish this task, TCR-CD3 uses a clonally distributed γδ disulfide-linked dimer (TCR) with immunoglobulin (Ig)-like variable domains Vα and Vβ. VαVβ forms a peptide-major histocompatibility complex (pMHC) binding site of six loops homologous to antibody complementarity determining regions (CDRs) 1, 2, and 3 (Garboczi et al., 1996; Garcia et al., 1996). Germline-encoded CDR1 and CDR2 have limited variability, whereas CDR3s are hypervariable. Vα and Vβ are connected to Ig-like constant domains, namely, Cα, Cβ, and Cζ, that are linked to the transmembrane regions (TMRs) through a stalk, called connecting peptide (CP). pMHC binding is signaled intracellularly by four non-covalently associated subunits (γ, δ, ε, and ζ), called CD3, organized into three dimers, namely, γε, δε, and ζζ, with the latter disulfide linked (Call et al., 2002). ε, γ, and δ exhibit an Ig-like extracellular domain (ECD) connected to TMRs by short CPs, whereas ζζ features a = 10-residue-long ECD. A recent TCR-CD3 cryoelectron microscopy (cryo-EM)
Cell Reports

Article

Figure A: Bar graph showing gene expression levels. The x-axis represents different conditions, and the y-axis represents expression levels.

Figure B: Bar graph displaying protein levels. The x-axis represents different conditions, and the y-axis represents protein expression.

Figure C: Graph showing the effect of protein expression on gene expression. The x-axis represents protein concentration, and the y-axis represents gene expression.

Figure D: Graph showing time-dependent changes in protein expression. The x-axis represents time, and the y-axis represents protein expression.

Figure E: Graph illustrating the effect of time on gene expression. The x-axis represents time, and the y-axis represents gene expression.

Figure F: Graph depicting the effect of condition on gene expression. The x-axis represents condition, and the y-axis represents gene expression.

Figure G: Graph showing the effect of condition on protein expression. The x-axis represents condition, and the y-axis represents protein expression.

Figure H: Graph illustrating the effect of treatment on cluster size. The x-axis represents treatment, and the y-axis represents cluster size.
structure at 3.7 Å (Dong et al., 2019) reconciles with mutational and nuclear magnetic resonance (NMR) studies (Call et al., 2002; He et al., 2015; Mariuzza et al., 2020; Natarajan et al., 2016) but reveals other features. VαβVβ projects forward with Cx interfacing with CD3ε ECD, Cβ interfacing with both CD3γ and CD3ε ECDs, and CD3γ and CD3ε (of αε) ECDs contacting each other. The TMRs of Cα(Cα-Cα) and Cβ(Cβ-Cβ) contact each other, Cε(Cε-Cε) contacts Cx and Cε, and Cγ contacts Cβ and Cε. The highly interlaced structure suggests a mutualistic contribution of each dimer to TCR-CD3 topology and cohesion. The intrinsically disordered intracellular tails of ε, γ, δ, and ζ, invisible in the cryo-EM structure, contain immunoreceptor tyrosine-based activation motifs (ITAMs) that become phosphorylated by constitutively active Lck kinase (Nika et al., 2010) within <1 s after pMHC binding (Acuto et al., 2008; Huse et al., 2007). The tails are anchored to the plasma membrane (PM) by basic amino acid residues and ITAM tyrosines that interact with negatively charged lipids and hydrophobic lipid core, respectively (Deford-Watts et al., 2009; Xu et al., 2008), perhaps preventing ITAM access of unliganded receptors by Lck. Early studies suggested that binding of agonist anti-CD3 antibody (Ab) induces conformational changes in TCR-CD3 that expose CD3 cytoplasmic tails (Gil et al., 2002). However, crystallographic studies of TCRβ ECD found extensive conformational changes in CDRs when bound to pMHC (Baker et al., 2012; Garcia et al., 2012) but no unambiguous or consistent changes beyond the TCRβ binding site. This finding led to suggest TCR-CD3 signaling models independent of conformational changes or in which pMHC binding was insufficient to induce conformational changes. These models posited that signaling is induced by TCR-CD3 clustering (Cochran et al., 2001; Yokosuka et al., 2005), co-receptors (CD8/CD4) (Delon et al., 1996), or segregation of CD45 tyrosine phosphatase (Davis and van der Merwe, 2006). Alternatively, mechanosensing-based models suggested that force generated by PM movements act on pMHC-bound TCR-CD3 to induce conformational changes and signaling (Kim et al., 2009; Liu et al., 2014). It was also proposed that TCR-CD3 clustering by pre-existing pMHC dimers induces conformational changes in CD3ε, but not directly in TCRβ (Gil et al., 2002; Minguet et al., 2007). Nevertheless, one crystal structure (Kjer-Nielsen et al., 2003) and a fluorescence-based study (Bedoeo et al., 2009) showed that pMHC induced conformational changes in Cx. Deuteron exchange (Hawse et al., 2012) and NMR investigations (Natarajan et al., 2017; Rangarajan et al., 2018) inferred changes in conformational dynamics of soluble TCRβ ECD when bound to pMHC. These changes mapped to where Cx and Cβ interface with ECDs of CD3 subunits (He et al., 2015; Natarajan et al., 2016). These studies could not rule in or out models proposed thus far nor did they prove that allosteric effects propagate from ζ to the CD3 subunits for signaling to occur. To challenge this impasse, we conceived a genetic perturbation analysis to help discriminate between models requiring or not molecular flexibility (i.e., conformational changes). Toward this goal, we questioned the functional role of ζ TMR that establishes a key physical connection between the pMHC-binding module and the CD3 signaling subunits. If TMRs are only required for TCR-CD3 solvation within the lipid bilayer and quaternary structure topology, TMR mutations should not change TCR-CD3 intrinsic signaling capability. In contrast, this could happen in mechanisms based on allosteric interaction or force. We gathered compelling evidence for TMR mutations in TCRβ and CD3γ that loosen quaternary structure cohesion and surprisingly augment signaling output. We also found that soluble monomeric pMHC agonists reduce TCR-CD3 quaternary structure cohesion and induce signal transduction, independently of co-receptor, clustering, or force. We propose that allosteric activation of TCR-CD3 by pMHC binding is the primary mover of T cell activation.

RESULTS

Gain-of-function mutations in β TMR

To question whether structural alterations in ζ TMR affected signaling, we used 1G4, an HLA-A2-restricted TCR specific for the 157-165 peptide from the NY-ESO-1 tumor antigen (Chen et al., 2009). Most residues of β TMR were individually replaced by alanine or leucine and the corresponding mutants tested for reconstituting TCR-CD3 surface expression in TCRβ-deficient Jurkat cells (J31.13) (Figure 1A). As reported earlier, JIK287 mutation drastically reduced TCR-CD3 surface expression (Alcover et al., 1990). However, alanine substitutions at βY281, βI285, βG286, βT289, βL290, βY291, and βS296 and leucine at βA292 showed only a ~20%–40% decrease of surface expression. Next, the majority of mutants showing 0%–40% reduction of surface expression was co-expressed together with wild-type (WT) 1G4 TCRβ in J31.13, and Erk activation (pErk) was monitored after stimulation with 6V-HLA-A2 tetramer (6V-A2)β (Figure 1B). Although no mutation significantly reduced Erk activation, both βA290 and βA291 significantly increased pErk. A gain of function was unexpected, even more so as βA290 and βA291 reduced TCR-CD3 surface expression (data in Figure 1B are not normalized for TCR-CD3 surface expression).

Figure 1. Gain-of-function mutations in β TMR
(A) CD3 surface expression of 1G4-WT and mutants. x ± SD of CD3+ cells, n = 3–8. Alx (red) and Leu (blue) substitution.
(B) pErk response of 1G4-WT and β mutants stimulated with 6V-A2α. x ± SEM of pErk+ cells; n = 3–6; unpaired t test, p = 0.0011 (βA290), p = 0.0092 (βA291). (C) pErk response of CD8β1 1G4-WT and 1G4-βA291 stimulated with 6V-A2α. Left, non-linear regression fit of 6V-A2α, nM versus pErk MFI, n = 3, R² = 0.82 (WT), 0.89 (βA291); EC₅₀ = 19.5 ± 5.5 (WT), 19.0 ± 3.1 (βA291). Right, x ± SD of max. pErk, n = 3, F-test p < 0.0001. See also Figure S1E.
(D) 6V-A2α binding to TCRβ WT or 1G4-βA291. Top, (6V-A2α) dose-dependent association, n = 3, non-linear regression fit, R² = 0.98 (WT), 0.97 (βA291), F-test (ns). Bottom, (6V-A2α) dissociation rate, n = 5, non-linear regression fit, R² = 0.84 (WT), 0.72 (βA291), F-test (ns).
(E) pα response of J76 1G4-WT or 1G4-βA291 stimulated with 6V-A2α. Left, non-linear regression fit of (6V-A2α), MFI versus pα MFI, n = 3, R² = 0.95 (WT), 0.96 (βA291). Right, x ± SD of max. pα, n = 4, unpaired t test p = 0.0078. See also Figure S1F.
(F) Basal pα in J76 1G4-WT or 1G4-βA291, pα MFI normalized to soluble CD3 MFI, n = 8, unpaired t test p < 0.0001. See also Figures S1H and S1I.
(G) FRAP of 1G4-WT or 1G4-βA291 treated (right) or not (left) with A770041. x ± SD of diffusion coefficient, D (μm²/s), n ≥ 20 cells, t test (ns).
(H) Lateral distribution by dSTORM of 1G4-WT or 1G4-βA291 treated (right) or not (left) with A770041. Plots represent pair auto-correlation analysis (g), x ± SD of ≥ 25 cells. Histograms show DBSCAN cluster analysis, x ± SD of cluster size per cell, t test (ns).
\(\beta A291\) heightens basal and ligand-induced signaling

To validate this apparently paradoxical observation, we focused on \(\beta A291\) and modified the experimental set up to improve data robustness. Thus, \(x\) and \(\beta\) of 1G4 were expressed as a single self-cleavable polypeptide (Figure S1A) from a doxycycline (dox)-inducible promoter in a TCR\(\zeta\)-deficient Jurkat cell line (J76). J76 expressed maximum levels of surface TCR-CD3 after 16–18 h of dox treatment and were tested soon after to reduce the potential risk of phenotypic drift of cells expressing 1G4 carrying \(\beta A291\) (hereafter, referred to as 1G4-\(\beta A291\)). As in 31.13 cells, 1G4-\(\beta A291\) expressed in J76 showed reduced surface expression (=30%) (cf. Figure 1A with Figure S1B). However, in most experiments, we lowered the dox concentration when inducing 1G4-WT to reduce the difference in surface expression with 1G4-\(\beta A291\) (to <5%) (Figure S1C). Moreover, in most flow cytometry analyses, J76 expressing 1G4-WT or mutant were barcoded by labeling with CellTrace violet, mixed before stimulation, and analyzed simultaneously. These stratagems simplified and made more robust the computation of differences in signaling output between the WT and mutant. Erk activation was retained as a sensitive and reliable readout of TCR-CD3 signal transduction and propagation as it depends on a cascade of early signaling steps, including ITAM phosphorylation, ZAP-70 activation, LAT signalosome assembly, and PLC-\(\gamma\)1 activation that generates \(pIP_3\) (for intracellular \([Ca^{2+}]\) increase) and DAG required for Ras activation by Ras-GRP (Acuto et al., 2005). Titration of (6V-A2)\(_3\) showed a shift in pErk response by 1G4-\(\beta A291\) toward higher sensitivity and revealed significantly higher Erk activation (Figure 1C). This result was not due to a higher Erk activation ceiling in 1G4-\(\beta A291\)-expressing cells (Figure S1D) nor to augmented binding of (6V-A2)\(_3\) to 1G4-\(\beta A291\) (Figure 1D, top and bottom panels), but it was consistent with the dose-response plot showing unchanged \(E_{50}\) between 1G4-\(\beta A291\) and 1G4-WT (Figure 1C and STAR Methods for computation). The higher maximal response of 1G4-\(\beta A291\) was compatible with a faster proofreading rate \(k_p\) for a receptor operating in a kinetic proofreading regimen (McKeithan, 1995). Indeed, fitting the data of Figure 1C into a minimal model of kinetic proof-reading (Dushek et al., 2011) showed that \(k_p\) for 1G4-\(\beta A291\) was considerably higher than that for 1G4-WT (Figure S1E), consistent with \(\beta A291\) enhancing TCR-CD3 intrinsic signaling capability (i.e., higher ligand potency). The gain of function was observed in CD8-deficient J76 (Figure 1C), ruling out that the \(\beta A291\) enhanced the TCR-CD3 interaction with co-receptor. Augmented signaling was also evident for \(\zeta\) phosphorylation (\(p\zeta\)) (Figures 1E and S1F), the earliest intracellular signaling event. Remarkably, anti-CD3c (UCHT1) Ab stimulation of 1G4-\(\beta A291\) also heightened \(p\zeta\) (Figure S1G), a triggering modality that by-passes pMHC binding, further supporting that \(\beta A291\) enhanced TCR-CD3 signaling. These data suggested that \(\beta A291\) might increase constitutive TCR-CD3 signaling detected by measuring \(p\zeta\) in non-stimulated cells. Indeed, basal \(p\zeta\) was significantly higher in cells expressing 1G4-\(\beta A291\) as compared to 1G4-WT (Figures 1F and S1H), and it was TCR signal specific as it disappeared after treatment by A770041 (Stachlewitz et al., 2005), a highly specific Lck inhibitor (Figure S1I). We then asked if \(\beta A291\) increased signaling by influencing TCR-CD3 lateral diffusion and/or distribution. However, fluorescence recovery after photo-bleaching (FRAP) found no significant difference in the diffusion coefficient (\(D\)) between 1G4-\(\beta A291\) and 1G4-WT (Figure 1G, left panel), which remained unchanged after A770041 treatment (Figure 1G, right panel).

Direct stochastic optical reconstruction microscopy (dSTORM) super-resolution microscopy found no statistically significant difference in the cluster size distribution formed by 1G4-\(\beta A291\) and 1G4-WT (histograms in Figure 1H). Although not statistically significant, the reproducible small increase of larger cluster frequency for 1G4-\(\beta A291\) disappeared after A770041 treatment (cf. auto-correlation function plots in left and right panels of Figure 1H), indicating it to be secondary to 1G4-\(\beta A291\) heightened basal signaling (Figure 1F) rather than \(\beta A291\) causing it. Finally, we questioned the potential cause(s) of mildly reduced 1G4-\(\beta A291\) surface expression. We excluded that \(\beta A291\) reduced \(\beta\) protein expression (Figure S1J) and considered that heightened basal signaling might decrease receptor surface expression by increasing its downregulation rate. However, exposure to A770041 for several hours increased surface expression of both 1G4-\(\beta A291\) and 1G4-WT in a similar proportion (=20%) but did not reduce their difference (Figure S1K). These data led us to consider if \(\beta A291\) modified the stability of TCR-CD3 quaternary structure that could reduce export to the PM due to increased negative triage by protein quality-control systems (Feige and Hendershot, 2013) of mutant versus WT.

\(\beta Y291\) contribution to TCR-CD3 quaternary structure cohesion

Non-ionic detergents used at a high concentration to quantitatively extract TCR-CD3 can dissociate TCR\(\beta\) from the CD3 modules (Testi et al., 1989). Presumably, this can be attributed to extensive substitution of natural boundary lipids by the detergent, with possible interference with TMR inter-helical interactions critical for TCR-CD3 quaternary structure cohesion (Alcover et al., 1990; Call et al., 2002). However, 0.5% of the non-ionic detergent n-dodecyl-\(\beta\)-D-maltopyranoside (DDM) allows quantitative extraction of stoichiometrically intact TCR-CD3 (Swamy et al., 2008; Figure S2A). Thus, if \(\beta A291\) altered TCR\(\beta\) cohesion with CD3 by unsettling TMR inter-helical interactions, 0.5% DDM extraction may show lower recovery of intact 1G4-\(\beta A291\) with respect to 1G4-WT. Figure S2B illustrates the experimental set up of chemically probing TCR-CD3 cohesion by DDM that we named DDM stability assay (DSA) (see STAR Methods for details). Membrane solubilisation by 0.5% DDM and pull-down (PD) of total \(\beta\) (mostly associated with \(\zeta\); Alcover et al., 2018) by the \(\beta\)-hemagglutinin (HA) tag was followed by quantitative immunoblot (IB) for \(\beta\) (with anti-HA Ab) and for each CD3 subunit. Anti-HA IB identified three \(\beta\) isoforms (named \(\beta_1\), \(\beta_2\), and \(\beta_3\); Figure 2A). \(\beta_3\) was the endo-H-sensitive endoplasmic reticulum (ER)-resident \(\beta\) isofrom (Figure S2C) that is assembled with \(\zeta\) and \(\gamma\), and \(\delta\) but not with \(\zeta\) (Alcover et al., 2018), as confirmed by \(\beta_3\) being undetected in CD3\(\zeta\) (PD (Figure S2D)). \(\beta_1\) and \(\beta_2\) were both endo-H-resistant (Figure S2C), although \(\beta_2\) was the only \(\beta\) isofrom associated with \(\zeta\) (Figure S2D). Thus, to evaluate the effect of \(\beta A291\) on TCR-CD3 complex cohesion, we used the IB signals of \(\beta\) isoforms, namely, \(\zeta\) and \(\epsilon\) (which includes \(\gamma\) and \(\delta\)). When \(\zeta/\beta_2\) was set equal to 1 for 1G4-WT (i.e., 100% recovery of intact TCR-CD3), reduced
Figure 2. βY291 contribution to TCR-CD3 quaternary structure cohesion

(A) Anti-HA (β-HA) pull-down (PD), and IB of 1G4-WT or 1G4-βA291. Top panels: left, representative IB, arrows indicate β-isoforms; right, x ± SD of ε/β and γ/β, n = 5, unpaired t test p < 0.0001. Bottom panels: input lysates, left, representative IB; right, x ± SD of β/actin, ε/actin and γ/actin, n = 5, unpaired t test (ns).

(B) β-HA PD and IB of 1G4-WT or 1G4-βA291. NR (non-reducing) conditions. Left, representative IB. Right, x ± SD of γ/β, n = 4, unpaired t test p < 0.0001.

(C) β-HA PD and IB of 1G4-WT or 1G4-βA291. NR conditions. Left, representative IB. Right, x ± SD of δ/β, n = 4, unpaired t test p < 0.0001.

(D) All-atom MDS of TCR-CD3 TMRs. TCRα (ochre), TCRβ (gray), CD3δ (blue), CD3ε (yellow), CD3γ (green), ζ (red). Left, snapshot of TCR-CD3 TMRs. Right, βY291 interactions with TCR-CD3 TMRs. Liquorice sticks show significant contacts of βY291 with TCRα, CD3γ, and CD3ε. See also Figure S2H.
cohesion between $\gamma$ and $\delta$ should result in $\gamma/\delta < 1$ (Figure S2B).

The DSA showed that $\gamma/\delta$ for 1G4-$\Delta$A291 was 0.2, indicating only 20% recovery of intact TCR-CD3 (or 80% loss of $\gamma$ recovery) after DDM solubilization (Figure 2A). To determine the effect of $\Delta$A291 on $\gamma$ and $\delta$ cohesion with $\alpha$, we used instead the sum of $\beta_1$, $\beta_2$, and $\beta_3$ (total $\beta$) IB signals that represented cytoplasmic and PM $\alpha$, of which most is associated with $\alpha$ (Alcover et al., 2018). $\gamma/\delta_1$ for 1G4-$\Delta$A291 was 0.5, indicating 50% reduced recovery of $\gamma$ (Figure 2A). These ratios did not change after A770041 treatment during dox induction of $\alpha$ expression (Figure S2E), excluding that reduced recovery concerned the pool of 1G4-$\Delta$A291 with increased basal $\alpha$. The considerable reduction of $\gamma$ (80%) and $\delta$ (50%) recovery for 1G4-$\Delta$A291 could not be the consequence of severance of the same magnitude of $\gamma$ from $\alpha$ (or from $\delta$ and $\gamma$) before export to the PM and/or at the PM, as only 20%-30% reduction of TCR-CD3 expression was observed by flow cytometry and incompatible with increased pMHC-induced signaling. Indeed, when TCR$\alpha$ is no longer in contact with $\gamma$, TCR$\gamma \delta \alpha$ alone cannot be exported to the T cell surface (Figure S2F; Alcover et al., 2018). Therefore, in the PM natural lipid environment, $\Delta$A291 only slightly perturbed TCR-CD3 quaternary structure cohesion (as the molecular dynamics simulations [MDs] show, see below), moderately reducing surface expression. However, substitution of natural boundary lipids by DDM severely corroded TCR-CD3 cohesion in 1G4-$\Delta$A291 and provoked partial physical detachment of $\gamma$ and $\delta$ from $\alpha$ during the solubilization. IB for $\gamma$ and $\delta$ revealed that $\Delta$A291 affected both $\gamma$ and $\delta$ cohesion with the rest of the complex, although asymmetrically, as it reduced $\gamma$ and $\delta$ recovery of 40% and 10%, respectively (Figures 2B and 2C). In the cryo-EM structure, $\gamma$A291 (note that Dong et al., 2019 refer to $\gamma$J292 as $\gamma$292) contacts mostly $\gamma$ and therefore, $\Delta$A291 can be expected to primarily affect the interaction between $\gamma$ and $\gamma$ in accordance with $\Delta$A291. However, $\Delta$A291 makes no contacts with $\gamma$ and $\delta$ (Dong et al., 2019) (see MDs below). Therefore, the DSA revealed a more complex picture, with $\Delta$A291 presumably indirectly affecting the interaction of both $\gamma$ and $\delta$ with the rest of the complex. To further understand the structural role of $\Delta$A291, we used the TMR atomic coordinates of the cryo-EM structure of the TCR-CD3 octamer (PDB: 6JXR) (Dong et al., 2019) to carry out all-atom MDs with $\gamma$WT and $\Delta$A291 in an asymmetric lipid bilayer, mimicking the lipid environment of TCR-CD3, thus adding dynamical insight into TCR-CD3 cohesion. Simulations for 1,250 ns confirmed considerable contacts of $\gamma$WT with $\delta$ (or $\gamma_\delta$), and $\gamma_\delta$ but not with $\alpha$ (Figures 2D and S2G) and revealed new contacts of $\gamma$ with $\gamma_\delta$ as well as significant reduction in six $\beta$ contacts with $\gamma$ ($\gamma_\delta$), five with $\gamma$, and four with $\alpha$ (Figure S2Q). Specifically, significant contacts were observed of $\gamma$A291 with $\gamma$N263, $\gamma$267, $\gamma$L129, $\gamma$G132, and $\gamma$L145 (Figures 2D, right panel, and S2H) and with $\gamma$133 and $\gamma$136, although the latter two were not significant (Figure S2H). No contacts of $\gamma$A291 with $\gamma$ were seen (Figure S2G). Simulations of the TMR octamer carrying $\Delta$A291 indicated new and augmented contacts of $\beta$ with $\gamma$ (or $\gamma_\delta$) and $\gamma$ (Figure S2I). In addition, although $\gamma$A291 still contacted $\gamma$L129, it completely lost interaction with $\gamma$G132, $\gamma$133, and $\gamma$136 (Figure S2J, middle panel). Likely, these changes were secondary to spatial re-adjustments due to the loss of the bulky tyrosine side chain. No contacts of $\gamma$A291 with $\gamma$ were observed. Overall, the simulations suggested that $\Delta$A291 reshuffled contacts with $\gamma$, with the net effect of increasing local compaction (Figure S2K), as indicated by a stabilization of their $\alpha$ helix crossing angle (Figure S2L). This result seemed to contradict the DSA data of $\Delta$A291 severely affecting the $\gamma_\delta$ interaction with the rest of the complex. Although a 1,250-ns timescale is relatively long for all-atom simulations of membrane proteins, it might be insufficient to capture re-adjustments of interchain contacts that possibly occur at larger timescales. $\Delta$A291 might affect the role of interfacial lipids in cementing $\alpha$ helix interactions (Gupta et al., 2017) that, when challenged with DDM, might cause crumbling of TMR cohesion in the mutant, despite augmented compaction by $\Delta$A291 elsewhere. However, reduced export to the PM was a good indicator that $\Delta$A291 (and other $\beta$ and $\gamma$TMR mutants, see below) promoted some instability of the complex, causing dynamical exposure of hydrophobic site and/or retention signals, detected and negatively triaged by protein quality-control systems (Feige and Hendershot, 2013). Comprehensively, these data suggested a positive correlation between TCR-CD3 reduced quaternary structure cohesion and activation of signal transduction.

**Loosening $\gamma$ association enhances signaling**

To corroborate this hypothesis, we investigated the phenotype of additional mutations in $\beta$ and $\gamma$ TMRs. We found that similar to $\Delta$A291, also $\beta$F291 and $\Delta$L291 mildly reduced TCR-CD3 surface expression, despite no decrease in $\beta$ expression (Figure 3A). Both mutations reduced the interaction of $\beta$ with $\gamma$ and $\delta$ (Figure 3B).

---

**Figure 3. Loosening $\gamma$ association enhances signaling**

(A) TCR-CD3 expression of 1G4-WT, 1G4-$\Delta$A291, 1G4-$\Delta$L291, and 1G4-$\Delta$F291 in CD8$^+$ J76. Left, $x$ is SEM of CD3 MFI in HA$^{\text{WT}}$, $n = 3$, unpaired t test $p < 0.0001$. Right, $x$ is SEM of $\beta$-HA MFI in HA$^{\text{WT}}$, $n = 3$, t test (ns).

(B) $\beta$-HA PD and IB of 1G4-WT or 1G4-$\beta$ mutants. Left, representative IB, the arrow indicates $\beta_2$ isoform. Middle, $x$ is SD of $\gamma$/$\beta_1$, $n = 3$, unpaired t test WT versus $\Delta$A291, WT versus $\Delta$L291 $p < 0.0001$, WT versus $\Delta$F291 $p < 0.01$. Right, $x$ is SD of $\delta$/$\beta_1$, $n = 3$, unpaired t test $p < 0.0001$.

(C) $\gamma$WT response of CD8$^+$ J76 1G4-WT or 1G4-$\Delta$F291 stimulated with (6V-A2)$^+$ L291. Left, non-linear regression fit of (6V-A2)$^+$ L291 versus pErk MFI, $n = 3$, $R^2 = 0.915$ (WT), $0.910$ (F291), $R^2 = 0.905$, F-test $p < 0.05$. See also Figure S3A (left).

(D) $\gamma$WT response of CD8$^+$ J76 1G4-WT or 1G4-$\Delta$L291 stimulated with (6V-A2)$^+$ L291. Left, non-linear regression fit of (6V-A2)$^+$ L291 versus pErk MFI, $n = 3$, $R^2 = 0.827$ (WT), $0.910$ (IL291), $R^2 = 0.905$, F-test $p < 0.0001$. See also Figure S3A (right).

(E) TCR-CD3 expression in CD8$^+$ J76 2H5-WT or 2H5-$\Delta$A291. Left, $x$ is SEM of CD3 MFI in HA$^{\text{WT}}$, $n = 3$, unpaired t test $p < 0.0001$. Right, $x$ is SEM of $\beta$-HA MFI in HA$^{\text{WT}}$, $n = 3$, t test (ns).

(F) $\beta$-HA PD and IB of 2H5-WT or 2H5-$\Delta$A291. Left, representative IB. Middle, $x$ is SD of $\gamma$/$\beta_1$, $n = 3$, unpaired t test $p < 0.0001$. Right, $x$ is SD of $\delta$/$\beta_1$, $n = 3$, unpaired t test $p = 0.01$.

(G) $\gamma$WT response of CD8$^+$ J76 2H5-WT or 2H5-$\Delta$A291 stimulated with (MART-1-A2)$^+$ L291. Left, non-linear regression fit of (MART-1-A2)$^+$ L291 versus pErk MFI, $n = 3$, $R^2 = 0.94$ (WT), $0.94$ (J292). Right, $x$ is SD of max. pErk, $n = 3$, F-test $p < 0.001$. See also Figure S3B.
and augmented pErk maximal response to (6V-A2), (Figures 3C and 3D), whose binding remained unchanged (Figure S3A). These three readouts ranked according to $|\beta|_{291} \geq |\beta|_{291} > |\beta|_{291} \geq |\beta|_{291}$ WT, presumably reflecting conservative or non-conservative replacements, and hence indicating a direct correlation between increased quaternary structure loosening and enhanced signaling. We then tested the effect of $|\beta|_{291}$ in 2H5, a HLA-A2-restricted TCR specific for the MART-1 tumor antigen (Circosta et al., 2009). Similar to 1G4-$|\beta|_{291}$, 2H5-$|\beta|_{291}$ showed reduced surface expression (Figure S3E) and TCR-CD3 cohesion (Figure S3F) and augmented pErk for equal (MART-1-A2), binding (Figures 3G and S3B). Conversely, mutation of $|\beta|$ TMR residues not involved in critical contacts (Dong et al., 2019), such as $|\beta|_{293}$ and $|\beta|_{303}$, showed no significant change of 1G4 surface expression (Figure S3C) or TCR-CD3 cohesion (Figures S3D and S3E) and no increase in (6V-A2)$_\alpha$-induced pErk (Figures S3F and S3G).

$|\beta|_{291}$ did not contact $\zeta$, but its mutation augmented basal (Figure 1F) and ligand-induced p$\zeta^\alpha$ (Figure 1E) and signal propagation. This was reminiscent of an allosteric interaction revealed by mutations (Changeux and Christopoulos, 2016; Volkman et al., 2001), e.g., $|\beta|_{291}$ inducing local re-adjustments but also distal functional effects, such as favoring exposure of $\zeta$ cytosolic tail to active-Lck. To investigate this possibility, we tested whether mutations in $\zeta$ TMR residues susceptible to loosing $\zeta$ contacts with subunits other than $|\beta|$ phenocopied mutations at $|\beta|_{291}$. TCR-CD3 cryo-EM structure and MDS indicated that $\zeta$ and $|\zeta|$ TMRs contacted only the N-terminal moiety of $|\beta|$ TMR (Figures 4A and S4A) and $\zeta$ TMR throughout (Figures 4B and S4B). However, $\zeta_2$ and $\zeta_1$ also contacted $\gamma$ (Figures 4C and S4C) and $\varepsilon$ (of the $\delta$) (Figures 4D and S4D), respectively. Specifically, MDS revealed that $\zeta_{38}I38$ contacted two residues of $\varepsilon$ (of the $\delta$) (Figures 4D and S4E, left panel) and $\zeta_{41}I41$ contacted two residues of $\gamma$ (Figures 4C and S4F, left panel), whereas $\zeta_{38}I38$ and $\zeta_{41}I41$ bulged toward the membrane lipids and made no contact with the complex. Thus, $\zeta_{38}I38$ and $\zeta_{41}I41$ were deemed capable of partially disturbing $\zeta_1$ and $\zeta_2$ interactions with $\varepsilon$ (of the $\delta$) and $\gamma$ but perhaps not with $|\beta|$. To verify this prediction, 1,250 ns all-atom simulations of TCR-CD3 octamer TMRs composed of $\zeta$ WT and $|\zeta|$ A41 and $|\zeta|$ A38 mutants were carried out. At the end of the simulations, snapshot alignment of the mutated and WT TMRs showed distortion in the contacts of $\zeta$ with $\delta\varepsilon$ (Figure 4E) and $\zeta_2$ with $\gamma$ (Figure 4G). As a consequence, $\zeta$ containing $|\zeta|$ A38 (3 out of 3 simulations) increased fluctuation relative to $\zeta|\beta|$ as compared to $\zeta|\beta|$ WT. This can be appreciated from the average spatial distribution plots of the Cx atoms of $\zeta$ relative to the Cx atoms of $|\beta|$ that showed broader density for both mutants (Figures 4F and 4H), although this was more pronounced for $|\zeta|$ A38. These results were indicative of $|\zeta|$ A38 and $|\zeta|$ A41 increasing $\zeta$ flexibility relative to $\zeta|\beta|$. Both mutants maintained some $\zeta$ contacts with the rest of the complex (Figures S4G–S4N). These results prompted us to test if, similar to the $|\beta|_{291}$ mutations, these $\zeta$ mutations also showed reduced surface expression, complex cohesion by DSA, and enhanced signaling. The data showed that $|\zeta|$ A38 or $|\zeta|$ A41 reduced 1G4 surface expression by $\approx 30\%$, for similar $\zeta$ expression (Figure 5A). The DSA showed that $|\zeta|$ A38 and $|\zeta|$ A41 reduced the $|\beta|$ ratio to $0.05$ and $0.25$ (95% and 75% loss of $\zeta$ recovery) respectively, without apparently affecting $\varepsilon$ cohesion with $|\beta|$. (Figures 5B and S5A). Thus, the DSA agreed with loosening of the $\zeta$ interaction with $\zeta|\beta|$ as predicted by the atomistic simulations. Perhaps, weakening direct interactions with CD3 TMRs and causing higher $|\zeta|$ mobility, $|\zeta|$ A38 and $|\zeta|$ A41 indirectly weakened the $\zeta$ interaction with $|\beta|$ as well, as revealed by DDM extraction. Simulations of larger timescales may provide clearer insights into dynamic alterations of $\zeta$ by $|\beta|_{291}$ producing direct effects on $|\varepsilon|$ and later indirect ones on $\zeta$. Importantly, similar to $|\beta|_{291}$, both $\zeta$ mutations conferred to 1G4 heightened the pErk response to (6V-A2)$_\alpha$, with a higher maximum than that of 1G4-WT (Figures 5C and 5D) for equal (6V-A2)$_\alpha$ binding (Figures S5B and S5C). We concluded that reduced cohesion between $\zeta|\beta|$ and $\zeta$ caused heightened signaling, rather than the mutations of $|\beta|_{291}$ per se. This conclusion strengthened the idea that reducing TCR-CD3 cohesion populated the active signaling state of TCR-CD3, i.e., it lowered the activation energy between two presumed functional states, inactive and active, with the latter initiating transmembrane signaling. These data make it unlikely that TCR-CD3 TMRs are just structural elements required for TCR-CD3 membrane solvation and architecture, as conformational change-independent models would imply. Rather, by analogy with allosterically regulated proteins that can be switched on or off by mutations distal from their active site(s) (Changeux and Christopoulos, 2016; Volkman et al., 2001) and considering recent NMR studies (He et al., 2020; Natarajan et al., 2016, 2017; Rangarajan et al., 2018), our data suggested that pMHC binding activated an allosteric cascade that loosened TCR-CD3 cohesion, including interactions with $\zeta$ TMRs serving
as a second-to-last relay before licensing ζ ITAM phosphorylation. These considerations prompted us to investigate this possibility.

**pMHC tetramer binding loosens ζβ association with ζ**

Conformational changes produced by pMHC binding may have distal effects that reduce contacts of CαCβ with δε and/or γε ECDs, eventually propagating to TMR contacts, including ζζ TMR, and resulting in reduced TCR-CD3 cohesion. If correct, the DSA should show reduced recovery of ζζ in ligand-engaged TCR-CD3 versus unengaged TCR-CD3. To test this idea, we aimed to capture DDM-solubilized pMHC-engaged TCR-CD3 and compare subunit recovery with unengaged TCR-CD3. Thus, 1G4-WT-expressing J76 was briefly stimulated with (9V-A2)₄, tetramerized with His-tagged streptavidin [(9V-A2)₄·His] (Figure S6A), ligand excess was removed, and cells rapidly solubilized with 0.5% DDM. Post-nuclear lysates were incubated with His-Cobalt beads for capturing (9V-A2)₄. This avoided this limitation, we initially used wtC51 (Irving et al., 2012), a 1G4 variant harboring four mutations in βCDR2 (Figure S6B) that confer a 15 nM diffusion constant (Kₒ) for NY-ESO-1₁₁₅₇₋₁₁₆₅-HLA-A₂ (Kₒ = 0.0013 s⁻¹ at 25°C). Computational modeling showed that NY-ESO-1₁₁₅₇₋₁₁₆₅-HLA-A₂ adopts a canonical orientation onto wtC51 VαVβ, which is almost indistinguishable from 1G4-WT (Figure S6B). (9V-A₂)₄·His induced robust wtC51-mediated Erk activation (Figure 6A, left panel) and allowed specific capture of engaged wtC51

**Figure 5. Loosening ζ association enhances signaling**

(A) TCR-CD3 expression in J76-1G4WT-CKO expressing WT or Cα38 or CαA1. Left, x ± SEM of CD3 MFI in HAbow gate, n = 3, unpaired t test p < 0.0001. Middle, representative IB. Right, x ± SD of ζ/actin, n = 3, unpaired t test (ns).

(B) β-HA PD and IB of 1G4-WT carrying WT or Cα38 or CαA1. Left, representative IB, the arrow indicates βδ isoform. Middle, x ± SD of c/βδ, n = 4, unpaired t test (ns). Right, x ± SD of ζ/βδ, n = 4, unpaired t test p < 0.0001. See also Figure S5A.

(C) pErk response of J76-1G4WT-CKO expressing WT or CαA1 stimulated with (6V-A2)₄. Left, non-linear regression fit of (6V-A2)₄ nM versus pErk MFI, n = 3, R² = 0.98 (WT), 0.99 (CαA1). Right, x ± SD of max. pErk, n = 3, F-test p < 0.0001. See also Figure S5B.

(D) pErk response of J76-1G4WT-CKO expressing WT or CαA1 stimulated with (6V-A2)₄. Left, non-linear regression fit of (6V-A2)₄ nM versus pErk MFI, n = 3, R² = 0.96 (WT), 0.97 (CαA1). Right, x ± SD of max. pErk, n = 3, F-test p < 0.0001. See also Figure S5C.
QM-α and 1G4-WT have superimposable canonical orientation when bound to NY-ESO-1-157-165 HLA-A2 (Figure S6B). Figure 6C showed that binding of (9V-A2)-α-His to QM-α induced strong Erk activation (Figure 6C, left panel) and reduced ã/b2 ratio (40%), which remained unchanged after A770041 treatment (Figure S6C). These observations were extended to 868, a TCR isolated from an HIV elite controller (Varale-Rohera et al., 2008). 868 recognizes the spontaneously mutated HIV p17 Gag-derived peptide SYNTIATL (6i) presented by HLA-A2, with a Kc of 5 nM (Koff, 0.0013 s⁻¹ at 4°C; Cole et al., 2017). Being a natural TCR directed at a viral antigen, 868 was ideal to validate the data obtained with in-vitro-modified TCRs against a tumor antigen. Binding of tetramerized ligand (6i-A2)α-His-stimulated strong Erk activation (Figure 6D, left panel) and weakened 868 quaternary structure cohesion, as shown by the reduced ã/b2 ratio (Figure 6D, middle and right panels). The occurrence of the same effect (i.e., structural changes) in three different TCRs by mere coincidence is highly unlikely but rather the consequence of the same cause, namely, ligand-induced conformational changes that modify critical contacts maintaining TCR-CD3 complex cohesion (Alcover et al., 1990; Call et al., 2002; Dong et al., 2019). Reduced ß cohesiveness was also observed in wtc51 when expressed in primary human T cells stimulated with (9V-A2)-α-His (Figure 6E), excluding non-physiological behavior of TCR-CD3 in the PM of Jurkat cells.

To date, it remains unclear whether anti-CD3 Abs used in clinical settings activate TCR-CD3 by mechanisms different from that of pMHC. To address this question, we slightly modified the DSA (STAR Methods). We used monobiotinylated Fab' of UCHT1 anti-CD3α as a proxy for minimally or non-stimulated receptor and monobiotinylated UCHT1 Ab to stimulate and weaken TCR-CD3 with streptavidin for IB analysis. Because TCR-CD3 was captured by CD3ε, ã/β and ã/ε ratios were used to assess TCR-CD3 cohesion. UCHT1 Ab binding reduced ã/β and ã/ε ratios and hence the cohesions of ε with β but less so with ß (Figure 6F). Similar observations were made in cells pre-treated with A770041 (Figures 6G and S6D) or reacted with UCHT1 at 0°C (Figures 6H and S6E). Taken together, these observations and the TMR mutant phenotype strongly suggested that TCR-CD3 signals intracellularly by an allosteric interaction propagating from the αβ binding site to the CD3 subunits and modifying critical contacts within the TMRs.

**Figure 6. pMHC tetramer binding loosens αβ association with ε**  
(A) J76 wtc51 stimulated with (9V-A2)-α-His + A770041. Left, representative pErk IB (n = 4). Middle, PD with anti-HA Ab (HA) (lanes 1, 3, 5) or His-Cobalt beads (His) (lanes 2, 4, 6) followed by IB for β and ε. Blocking was with HA peptide or imidazole. The arrow indicates β2 isofrom. Right, x ± SD of ã/β2, n = 5–6, unpaired t test p < 0.0001.  
(B) J76 wtc51 stimulated with (9V-A2)-α-His at 0°C. Left, representative pErk IB (n = 4). Middle, β-HA (lanes 1, 3) or His (lanes 2, 4) PD and IB for β and ε. The arrow indicates β2 isofrom. Right, x ± SD of ã/β2, n = 4, unpaired t test p < 0.0001.  
(C) J76 QM-α stimulated with (9V-A2)-α-His. Left, representative pErk IB (n = 3). Middle, β-HA (lanes 1, 4) or His (lanes 2, 3) PD and IB for β and ε. The arrow indicates β2 isofrom. Right, x ± SD of ã/β2, n = 3, unpaired t test p < 0.01.  
(D) J76 868 stimulated with (6i-A2)-α-His. Left, representative pErk IB (n = 3). Middle, β-HA (lanes 1, 3) or His (lanes 2, 4) PD and IB for β and ε. The arrow indicates β2 isofrom. Right, x ± SD of ã/β2, n = 3, unpaired t test p < 0.01.  
(E) Primary T cells expressing wtc51 stimulated with (9V-A2)-α-His. Left, representative pErk IB (n = 3). Middle, β-HA (lanes 1, 3) or His (lanes 2, 4) PD and IB for β and ε. The arrow indicates β2 isofrom. Right, x ± SD of ã/β2, n = 3, unpaired t test p < 0.001.  
(F) J76 1G4 ± UCHT1-Fab' or UCHT1-Ab. Left, streptavidin (SA)-mediated PD and IB for β, ε, and χ. Right, x ± SD of ã/β, ã/ε, and ã/χ, n = 4, unpaired t test p = 0.0023, p < 0.0001.  
(G) J76 1G4 ± A770041 incubated or not with UCHT1-Fab' or UCHT1-Ab. Left, SA-mediated PD and IB for β, ε, and χ. Right, x ± SD of ã/β, ã/ε, and ã/χ, n = 3, unpaired t test p = 0.0007, p = 0.0494. See also Figure S6D.  
(H) J76 1G4 ± UCHT1-Fab' or UCHT1-Ab at 0°C. Left, SA-mediated PD and IB for β, ε, and χ. Right, x ± SD of ã/β, ã/ε, and ã/χ, n = 3, unpaired t test p < 0.0001, p = 0.0218. See also Figure S6E.
Figure 7. Monovalent pMHC in solution triggers TCR-CD3 untying and intracellular signaling

(A) J76 wt051 + A770041 stimulated or not with sm-9V-A2 were lysed and subjected to PD with anti-HA Ab or Talon beads. First panel, anti-HA (b-HA) (lanes 1, 3) or Talon beads (His) (lanes 2, 4, 6) PD and IB for b and z. The arrow indicates b2 isoform. Second panel, x ± SD of z/b2, n = 3, unpaired t test p < 0.0001 and p < 0.01. Third panel, representative pErk IB. Fourth panel, x ± SD of pErk, n = 3, unpaired t test p < 0.05.

(B) CD8+ J76 wt051 stimulated or not with sm-9V-A2 were processed as in (A). First panel, b-HA (lanes 1, 3) or His (lanes 2, 4) PD and IB for b and z. The arrow indicates b2 isoform. Second panel, x ± SD of z/b2, n = 3, unpaired t test p < 0.01. Third panel, representative pErk IB. Fourth panel, x ± SD of pErk, n = 3, unpaired t test p < 0.05.

(legend continued on next page)
However, we found that sm-9V-A2, controlled by SEC-MALs for being monodisperse (Figure S7B), did induce robust pErk in both CD8-efficient (Figure 7A) and CD8-deficient (Figure 7B) J76 cells expressing wtc51 and erased by A770041 (Figure 7A). Erk activation by sm-9V-A2 was dose dependent (Figure S7F), with as little as 3 nM inducing 50% of the maximum and occurred at 2 min after sm-9V-A2 addition (Figure S7G), similar to (9V-A2) stimulation of 1G4-WT (Paster et al., 2015), although (9V-A2) generally induced a stronger pErk response. We obtained similar results with 868 in the presence or absence of a CD8 co-receptor (Figures 7C, 7D, and S7C) and with QM-α without CD8 (Figure S7H). Non-specific adsorption of sm-pMHC onto the J76 cell membrane during the stimulation assay was negligible even at the highest sm-9V-A2 concentration (Figure S7I). This made it unlikely that signaling was the consequence of sm-9V-A2 non-specific adsorption to the cell surface and ligand cross-presentation rather than direct stimulation by soluble sm-9V-A2. Moreover, we experimentally tested whether even this negligible amount of non-specifically bound sm-9V-A2 on J76 cells could be stimulatory. However, we did not detect any Erk activation (Figure S7J). Multiple reasons can explain why our data apparently conflict with previous observations. First and foremost, we used TCRs of reduced k_{off} (higher-affinity range) for pMHC, including a natural one (868), sm-pMHC ligands of low-medium affinity range (μM) can be expected to induce low/non-sustained [Ca^{2+}] increase, whose ramp-up requires a complex cascade of additional events (Irvine et al., 2002; Lewis, 2020), including co-receptor implication (Delon et al., 1998; Minguet et al., 2007). Also, sm-pMHC engages TCR-CD3 without immediately clustering it, contrary to pMHC tetramers that provide this critical signaling-reinforcing effect (see Discussion). Moreover, membrane-tethered pMHC has lower degree of freedom than soluble pMHC, a property that sensibly increases pMHC on-rate (Huppa et al., 2010; O’Donoghue et al., 2013). Comprehensively, our genetic, biochemical, MDS, and functional data constitute substantial evidence that TCR-CD3 is a genuine allosteric device. We name this model “TCR-CD3 allosteric relaxation” (Figure S7K) as a mechanism sufficient to incite initial T cell activation solely by pMHC binding.

**DISCUSSION**

To gather insight into TCR-CD3 signaling, we used a genetic perturbation approach and found that TMR mutations that loosened cohesion between TCRξβ and CD3ζ increased the agonist’s potency. This phenotype mimicked pMHC agonist binding that also reduced cohesion between TCRξβ and CD3ζ. These convergent results suggested that weakening of TCR-CD3 TMR contacts is a key step in an allosteric mechanism initiated by pMHC binding and culminating in ITAM phosphorylation. We favor the idea that conformational changes occurring upon pMHC binding propagate to Cαβp ECDS, where they contact the CD3 subunits (Beddoo et al., 2009; He et al., 2020; Natarajan et al., 2017; Rangarajan et al., 2018). The ECDS and TMRs of TCRξβ, CD3δζ, and CD3γε show an extended intra-dimer interface (Dong et al., 2019). Moreover, CD3δζ and CD3γε interact much more with TCRξβ than with each other. It is therefore conceivable that pMHC binding induces reshuffling of contacts between ECD dimers, loosening CD3δζ and CD3γε from TCRξβ. This may result in slight rotation and/or translation of CD3δζ and/or CD3γε vis-à-vis TCRξβ. The mechanical rigidity of ε, δ, and γ CPs (Alcover et al., 2018) could transmit these movements to the respective TMRs, resulting in local rearrangements of helix-helix packing and perhaps of interfacial lipids (Gupta et al., 2017; Figure S7K). Consistently, mutations of ε Cys-Cys loop affect TCR-CD3 signaling (Wang et al., 2009). Ligand-activated relaxed TCR-CD3 might reduce contacts between TMRs of αβεζ, making εζ prone to detaching from the rest of the complex by DDM during membrane extraction. As our data suggest, TMR quaternary structure relaxation activated by pMHC (or anti-CD3 Ab) or by TMR mutations promotes ITAM accessibility by active-Lck (Nika et al., 2010), which would require conformational changes of membrane-tethered CD3 intracellular tails (Xu et al., 2008). These are intrinsically disordered, and hence, they may lack mechanical rigidity required to respond to TMR movements. We suggest that subtle untying of TMRs may reduce the grip of CD3 intracellular tails to the membrane and favor ITAM tyrosine exposure (Figure S7K). Phosphatidylinerine (PS) (Xu et al., 2008) and PIP2 (Chouaki Benmansour et al., 2018) appear to keep CD3 tails retracted onto the PM. A possibility is that TMR octamer rearrangement permits fast exchange of PIP2 and PS with neutral lipids that may reduce CD3ζ and ε tail interaction with the lipid bilayer (Figure S7K), augmenting ITAM tyrosine exposure to active-Lck. Changes in cholesterol interacting with TMR helices (Swamy et al., 2016; Wang et al., 2016) and/or ITAM tyrosines might be part of this mechanism. An agonist anti-CD3ε mAb produced a similar gain of function in TMR mutants, in agreement with CD3ε ECD lying on a conformational trajectory activated by pMHC.

We showed that binding of sm-pMHC to membrane-bound or detergent-solubilized TCR-CD3 suffices to induce TCR-CD3 relaxation and signal transduction. Stimulation of TCR-CD3 by sm-pMHC alone agrees with a genuine allosteric mechanism, as hinted by our genetic perturbation analysis. Allosteric activation occurred without co-receptor or clustering or force, making
actomyosin-induced membrane movements required for mechanosensing (Das et al., 2015; Kim et al., 2009; Liu et al., 2014) dispensable for signal ignition. A $K_d$ of 7 μM could not allow to show quaternary structure relaxation of 9V-A2-bound versus free 1G4 TCR. However, this was possible with 1G4 variants wtc51 and QM-$\alpha$ capable of binding 9V-A2 with a $K_d$ of 15 nM and 140 nM, which is within the physiological $K_d$ range for pMHC agonists (Aleksic et al., 2012; Cole et al., 2007; Stone et al., 2009). A third example was 868, a cytotoxic T lymphocyte (CTL)-derived anti-HIV strong TCR pMHC binder. However, the DSA may limit the conclusions that can be drawn about weaker ligand interactions, and future work is required to address this conclusively. Nonetheless, allosterically regulated signaling by TCR-CD3 should be valid for the entire range of pMHC affinities, as independent studies showed that allosteric changes in TCR$\zeta$ occurred upon pMHC binding of $K_d$ ranging between 5 and 0.04 μM (Beddoe et al., 2009; Natarajan et al., 2017; He et al., 2020; Rangarajan et al., 2018).

Allosterically induced interactions propagate at distances of nanometers in tens of μs to 1–2 ms (Kern and Zuiderweg, 2003; Natarajan et al., 2017; Rangarajan et al., 2018), which is much faster than the fastest half-lives (=200 ms) of pMHC-TCR$\zeta$ interactions (e.g., positively selecting pMHC; Hong et al., 2018). Thus, it is conceivable that TCR$\zeta$ binding of very weak or strong agonists can activate TCR-CD3 by allosteric regulation. Allosterically regulated receptor tyrosine kinases (RTKs) and G-protein coupled receptors (GPCRs) function with allosteric modality when binding ligands of a wide difference in affinity (Freed et al., 2017; Furness et al., 2016; Lane et al., 2017). Early work did not detect a $[Ca^{2+}]$ increase by the pMHC monomer (Boniface et al., 1998), unless CD8 was co-engaged (Delon et al., 1998). This apparent conflict with our data can be reconciled by considering differences in sensitivity of the outputs measured (i.e., $[Ca^{2+}]$, versus pErk) and increased pMHC dwell-time binding in our experiments. Moreover, membrane-anchored pMHCs have considerably increased $k_{on}$ (and little or no change in $k_{off}$) compared to soluble pMHC (Huppa et al., 2010; O’Donoghue et al., 2013), indicating more effective entropically-driven signaling by the former. Moreover, $[Ca^{2+}]$, high amplitude and duration require sustained TCR$\zeta$ engagement (Irvine et al., 2002; Lewis, 2020) achieved by higher lateral ordering of signaling complexes in micro-clusters at the immunological synapse (Varma et al., 2006). Co-receptors and clustering allow recording robust intracellular signaling required for full T cell activation, which may not be required for just igniting TCR-CD3 signal transduction as sm-pMHC alone does.

Reduced $k_{off}$ of the TCR-pMHC interaction is observed when subjected to $\approx 10$–20 pN pulling force, meaning “catch-bond” formation (Liu et al., 2014). However, mechanical force generated by membrane fluctuations and/or dedicated actin protrusions occur on a timescale of several seconds, which is two to three orders of magnitude slower than allosteric changes. Thus, pMHC-induced initial signal transduction may occur without mechanical force. Interestingly, recent biophysical data suggest that force developed between membrane-anchored TCR-CD3 and pMHC is of low magnitude (≈ 2pN) (Göhring et al., 2021). Perhaps, low-amplitude force may extend purely allosterically induced interactions.

Changes in conformational dynamics have long-range consequences of functional relevance, a mechanism known as dynamic allosteric relying on conformational entropy (Tzeng and Kalodimos, 2012). Conformational entropy cannot be frequently observed in proteins’ crystalline state, as it is unlikely to capture a higher-energy (activated) state. However, NMR can correlate fast local conformational changes (ps, ns) occurring at distant sites over timescales of μs to ms and distances of nm (Kern and Zuiderweg, 2003; Natarajan et al., 2017). Dynamic allostery may apply to TCR$\zeta$, as pMHC binding induces changes in conformational dynamics at distal H3, H4 helices, and FG loop of C$\gamma$ and C$\zeta$ AB loop (Beddoe et al., 2009; He et al., 2020; Natarajan et al., 2017; Rangarajan et al., 2018), with the latter having been captured thus far in only a single crystal structure (Kjer-Nielsen et al., 2003).

Our data should help reconcile controversies about the TCR-CD3 signaling mechanism. Thus, pMHC co-engagement by TCR and co-receptor is conditional on initial TCR-CD3 signaling (Casas et al., 2014; Jiang et al., 2011), and catch-bonding appears to depend in part on TCR signaling (Hong et al., 2018). We found evidence for enhanced basal signaling inducing clustering that is erased by Lck inhibition. These data suggest that all these events are instigated by an initial mechanism of allosteric nature induced solely by pMHC binding. Thus, co-receptor engagement, receptor clustering, shielding from PTPs, and actomyosin-driven mechanical force may stabilize/potentiate initial allosterically induced signaling by helping reduce physical and chemical noise and augmenting/stabilizing signals of narrow amplitude and duration initiated by sparse engagement of pMHC (Brameshuber et al., 2018).

Binding of different CDR interfaces might activate different conformational changes. If so, ligand potency may reflect combinations of binding kinetics and conformational trajectories. Alternatively, different ligand-receptor pairs may induce similar conformational trajectories. Future functional studies with TCR-CD3 binding pMHC with non-canonical orientations (Adams et al., 2011), MDSSs, native nanodiscs, and genetic perturbation should help clarify this question and provide further insights on the mechanism that triggers TCR-CD3 signaling.

**Limitations of the study**

We have shown that signaling is activated by pMHC-induced changes of TCR-CD3 quaternary structure. For this study, we had to use TCRs of reduced $k_{off}$ for pMHC, as limitations of DSA did not allow us to show the same effect for weak agonists. However, structural studies have shown allosteric changes occurring upon C$\zeta$C$\gamma$ binding to medium-range agonists. Moreover, conformational change propagation occurs at two orders of magnitude faster than the dwell-time of the weakest agonists, such as that of self-pMHC. Although this finding supports our conclusions, further work is required to formally demonstrate their validity regardless of TCR affinity for pMHC.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
RESOURCE AVAILABILITY
○ Lead contact
○ Materials availability
○ Data and code availability

EXPERIMENTAL MODEL AND SUBJECT DETAILS
○ Cell lines
○ Primary T cells

METHOD DETAILS
○ DNA constructs and cloning
○ CRISPR/Cas9-mediated knock-out
○ TCR-CD3 expression
○ Preparation of pMHC monomers and tetramers
○ Preparation of UCHT1-Fab' fragment
○ Flow cytometry
○ Mathematical modeling
○ Biochemical analysis of the TCR-CD3 complex
○ Ligand-induced TCR-CD3 quaternary structure changes
○ Microscopy
○ Atomic force microscopy
○ Modeling of the 1G4 TCR affinity mutants

QUANTIFICATION AND STATISTICAL ANALYSIS
○ Flow cytometry
○ Pull-down and Immunoblotting
○ Microscopy
○ Simulations
○ Modeling
○ Significance

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.celrep.2021.109375.

ACKNOWLEDGMENTS

AUTHOR CONTRIBUTIONS

DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: October 7, 2020
Revised: May 5, 2021
Accepted: June 18, 2021
Published: July 13, 2021; corrected online: July 30, 2021

REFERENCES


**STAR METHODS**

**KEY RESOURCES TABLE**

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse anti-human AF647 CD3ζ pY142 mAb</td>
<td>BD Bioscience</td>
<td>Cat# 558489; RRID:AB_647152</td>
</tr>
<tr>
<td>Mouse anti-human PE CD3ζ pY142 mAb</td>
<td>BD Bioscience</td>
<td>Cat# 558448; RRID:AB_647237</td>
</tr>
<tr>
<td>Mouse anti-human AF647 CD3ε mAb</td>
<td>BioLegend</td>
<td>Cat# 300422, RRID:AB_493092</td>
</tr>
<tr>
<td>Mouse anti-human BV421 CD3ε mAb</td>
<td>BioLegend</td>
<td>Cat# 300434, RRID:AB_10962690</td>
</tr>
<tr>
<td>Mouse anti-human PE CD3ε mAb</td>
<td>BioLegend</td>
<td>Cat# 300456, RRID:AB_2564150</td>
</tr>
<tr>
<td>Mouse biotinylated anti-human CD3ε mAb</td>
<td>BioLegend</td>
<td>Cat# 300404, RRID:AB_314058</td>
</tr>
<tr>
<td>Rabbit anti-human AF647 pErk mAb</td>
<td>Cell Signaling Technology</td>
<td>Cat# 4375, RRID:AB_10706777</td>
</tr>
<tr>
<td>Rabbit anti-pTyr416 Src polyclonal Ab</td>
<td>Cell Signaling Technology</td>
<td>Cat# 2101, RRID:AB_331697</td>
</tr>
<tr>
<td>Rabbit anti-human ERK 1/2 polyclonal Ab</td>
<td>Cell Signaling Technology</td>
<td>Cat# 9107, RRID:AB_10695739</td>
</tr>
<tr>
<td>Rabbit anti-HA mAb</td>
<td>Cell Signaling Technology</td>
<td>Cat# 3724, RRID:AB_1549585</td>
</tr>
<tr>
<td>Rabbit anti-human CD3 γ mAb</td>
<td>Abcam</td>
<td>Cat# 134096</td>
</tr>
<tr>
<td>Rabbit anti-human CD3 δ polyclonal Ab</td>
<td>GeneTex</td>
<td>Cat# GTX105811, RRID:AB_11166991</td>
</tr>
<tr>
<td>Mouse AF488 anti-HA mAb</td>
<td>Cell Signaling Technology</td>
<td>Cat# 2350, RRID:AB_491023</td>
</tr>
<tr>
<td>Mouse AF647 anti-HA mAb</td>
<td>Cell Signaling Technology</td>
<td>Cat# 3444, RRID:AB_10693329</td>
</tr>
<tr>
<td>Rat anti-human CD3ε mAb</td>
<td>Cell Signaling Technology</td>
<td>Cat# 4443, RRID:AB_560945</td>
</tr>
<tr>
<td>Mouse anti-CD3ε mAb</td>
<td>Santa Cruz Biotechnology</td>
<td>Cat# sc-1239, RRID:AB_627020</td>
</tr>
<tr>
<td>Rabbit anti-CD3ε pY142 mAb</td>
<td>Abcam</td>
<td>Cat# ab68235, RRID:AB_11156649</td>
</tr>
<tr>
<td>Mouse anti-Actin mAb</td>
<td>Merck Millipore</td>
<td>Cat# MA81501, RRID:AB_2223041</td>
</tr>
<tr>
<td>Mouse anti-pTyr mAb</td>
<td>Merck Millipore</td>
<td>Cat# 05-321, RRID:AB_309678</td>
</tr>
<tr>
<td>Mouse anti-human CD3ε mAb</td>
<td>BioXCell</td>
<td>Cat# BE0231, RRID:AB_2687713</td>
</tr>
<tr>
<td>Mouse anti-HLA-A, B, C mAb</td>
<td>BioLegend</td>
<td>Cat# 311423, RRID:AB_1877080</td>
</tr>
<tr>
<td>Mouse anti-human APC HLA-A2 mAb</td>
<td>BioLegend</td>
<td>Cat# 343308, RRID:AB_2561567</td>
</tr>
<tr>
<td>Rabbit anti-CD3ε polyclonal Ab</td>
<td>San José et al., 1998</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Bacterial and virus strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>E.coli</em> DH5α Competent Cells</td>
<td>Thermo Fisher</td>
<td>Cat# 18265-017</td>
</tr>
<tr>
<td><em>E.coli</em> Stbl3 Competent Cells</td>
<td>Invitrogen</td>
<td>Cat# C7373-03</td>
</tr>
<tr>
<td><strong>Chemicals, peptides, and recombinant proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10X Tris/Glycine/SDS</td>
<td>Biorad</td>
<td>Cat# 161-0772</td>
</tr>
<tr>
<td>16% Formaldehyde (w/v), Methanol-free</td>
<td>Thermo Fisher</td>
<td>Cat# 28908</td>
</tr>
<tr>
<td>2-Mercaptoethylamine-HCl</td>
<td>Thermo Fisher</td>
<td>Cat# 20408</td>
</tr>
<tr>
<td>Annexin-V-AF647</td>
<td>BioLegend</td>
<td>Cat# 640912</td>
</tr>
<tr>
<td>Annexin-V-PE</td>
<td>BioLegend</td>
<td>Cat# 640908</td>
</tr>
<tr>
<td>Alexa Fluor 488 C6 Maleimide</td>
<td>Thermo Fisher</td>
<td>Cat# A10254</td>
</tr>
<tr>
<td>Alexa Fluor 647 C6 Maleimide</td>
<td>Thermo Fisher</td>
<td>Cat# A20347</td>
</tr>
<tr>
<td>Amicon Ultra 15 mL centrifugal filter units</td>
<td>Millipore</td>
<td>Cat# UFC901008</td>
</tr>
<tr>
<td>Anti-HA-conjugated agarose beads</td>
<td>Sigma Aldrich</td>
<td>Cat# AL2095</td>
</tr>
<tr>
<td>A770041 Lck inhibitor</td>
<td>Axon Medchem</td>
<td>Cat# 1698</td>
</tr>
<tr>
<td>BamH1</td>
<td>New England Biolabs</td>
<td>Cat# R0136</td>
</tr>
<tr>
<td>BD Cytofix buffer</td>
<td>BD Biosciences</td>
<td>Cat# 554655</td>
</tr>
<tr>
<td>BD PharmFlow Perm/Wash buffer 1</td>
<td>BD Biosciences</td>
<td>Cat# 55785</td>
</tr>
<tr>
<td>Benzonase Nuclease</td>
<td>Millipore</td>
<td>Cat# 71206-25KUN</td>
</tr>
<tr>
<td>BirA kit</td>
<td>Avidity</td>
<td>Cat# BirA500</td>
</tr>
<tr>
<td>Bovine serum albumin (BSA)</td>
<td>Sigma Aldrich</td>
<td>Cat# A4503-100G</td>
</tr>
</tbody>
</table>

(Continued on next page)
<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bug Buster protein extraction reagent</td>
<td>Millipore</td>
<td>Cat # 70584-4</td>
</tr>
<tr>
<td>Catalase</td>
<td>Sigma Aldrich</td>
<td>Cat # C100</td>
</tr>
<tr>
<td>CellTrace™ Violet</td>
<td>Thermo Fisher</td>
<td>Cat # C34557</td>
</tr>
<tr>
<td>Centricron® Plus-70 centrifugal filter units</td>
<td>Millipore</td>
<td>Cat # UFC703008</td>
</tr>
<tr>
<td>Cysteamine MEA</td>
<td>Sigma Aldrich</td>
<td>Cat # 30070</td>
</tr>
<tr>
<td>Disposable PD 10 desalting column</td>
<td>G&amp;E Healthcare</td>
<td>Cat # 17-0851-01</td>
</tr>
<tr>
<td>DMEM</td>
<td>Sigma Aldrich</td>
<td>Cat # D6429</td>
</tr>
<tr>
<td>DMSO</td>
<td>Sigma Aldrich</td>
<td>Cat # D8418-100ML</td>
</tr>
<tr>
<td>Doxycycline hyclade</td>
<td>Sigma Aldrich</td>
<td>Cat # D9891-10G</td>
</tr>
<tr>
<td>DpnI</td>
<td>New England Biolabs</td>
<td>Cat # R0176</td>
</tr>
<tr>
<td>EasySep Human CD8 T cell isolation kit</td>
<td>STEMCELL</td>
<td>Cat # 17953</td>
</tr>
<tr>
<td>EcoR1</td>
<td>New England Biolabs</td>
<td>Cat # R0101</td>
</tr>
<tr>
<td>Endoglycosidase H (endo H)</td>
<td>New England Biolabs</td>
<td>Cat # P0702S</td>
</tr>
<tr>
<td>EZ-Link Maleimide-PEG2 biotin</td>
<td>Thermo Fisher</td>
<td>Cat # 21901BID</td>
</tr>
<tr>
<td>Fetal bovine serum (FBS)</td>
<td>GIBCO</td>
<td>Cat # 10500-064</td>
</tr>
<tr>
<td>Glucose</td>
<td>Sigma Aldrich</td>
<td>Cat # G8270</td>
</tr>
<tr>
<td>Glucose Oxidase</td>
<td>Sigma Aldrich</td>
<td>Cat # G2133</td>
</tr>
<tr>
<td>Glutamine</td>
<td>GIBCO</td>
<td>Cat # A2916801</td>
</tr>
<tr>
<td>HA peptide</td>
<td>Sigma Aldrich</td>
<td>Cat # I2149</td>
</tr>
<tr>
<td>His-Pur Cobalt Resin</td>
<td>Thermo Fisher</td>
<td>Cat # 89964</td>
</tr>
<tr>
<td>His-Streptavidin (AA 25-183) protein (His tag)</td>
<td>Antibodies Online</td>
<td>Cat # ABIN666648</td>
</tr>
<tr>
<td>HLA-A2-SLYNTIATL (6I-A2) monomer</td>
<td>Cole et al., 2017</td>
<td>N/A</td>
</tr>
<tr>
<td>Human T-activator CD3/CD28 Dynabeads</td>
<td>Thermo Fisher Scientific</td>
<td>Cat # 11161D</td>
</tr>
<tr>
<td>Human serum</td>
<td>Sigma Aldrich</td>
<td>Cat # H4522</td>
</tr>
<tr>
<td>ICAM-1 protein, recombinant human</td>
<td>R&amp;D Systems</td>
<td>Cat # 720-IC-050</td>
</tr>
<tr>
<td>Imidazole</td>
<td>Sigma Aldrich</td>
<td>Cat # I202-500G</td>
</tr>
<tr>
<td>Iodoacetamide</td>
<td>Sigma Aldrich</td>
<td>Cat # I6125</td>
</tr>
<tr>
<td>Ionomycin</td>
<td>Sigma Aldrich</td>
<td>Cat # I0634</td>
</tr>
<tr>
<td>Lysonase (Lysozyme + Benzonase)</td>
<td>Millipore</td>
<td>Cat # 71230-3</td>
</tr>
<tr>
<td>MART-1 peptide (&gt; 95% purity by HPLC)</td>
<td>Cambridge Peptides Inc.</td>
<td>N/A</td>
</tr>
<tr>
<td>n-Dodecyl β-D-maltoside (DDM)</td>
<td>Millipore</td>
<td>Cat # 324355-SGM</td>
</tr>
<tr>
<td>Non-essential amino acids solution</td>
<td>GIBCO</td>
<td>Cat # 11140050</td>
</tr>
<tr>
<td>Not 1</td>
<td>New England Biolabs</td>
<td>Cat # R0189</td>
</tr>
<tr>
<td>NuPAGE LDS Sample Buffer</td>
<td>Invitrogen</td>
<td>Cat # NP0007</td>
</tr>
<tr>
<td>NuPAGE Sample Reducing Agent</td>
<td>Invitrogen</td>
<td>Cat # NP009</td>
</tr>
<tr>
<td>NY-ESO-1 peptides (&gt; 95% purity by HPLC)</td>
<td>Cambridge Peptides Inc.</td>
<td>N/A</td>
</tr>
<tr>
<td>PEG-it™</td>
<td>SBI</td>
<td>Cat # LV810A-1</td>
</tr>
<tr>
<td>PEIpro</td>
<td>Polypus</td>
<td>Cat # 115-010</td>
</tr>
<tr>
<td>Pepsin</td>
<td>Thermo Fisher</td>
<td>Cat # 20343</td>
</tr>
<tr>
<td>Phosphate Buffer Saline (PBS)</td>
<td>Sigma Aldrich</td>
<td>Cat # P4417</td>
</tr>
<tr>
<td>Phorbol 12-myristate 13-acetate (PMA)</td>
<td>Sigma Aldrich</td>
<td>Cat # P1585</td>
</tr>
<tr>
<td>Phycoerythrin-conjugated streptavidin</td>
<td>Sigma Aldrich</td>
<td>Cat # S4762-5MG</td>
</tr>
<tr>
<td>Pme1</td>
<td>New England Biolabs</td>
<td>Cat # R0560</td>
</tr>
<tr>
<td>Polybrene</td>
<td>Sigma Aldrich</td>
<td>Cat # 28728554</td>
</tr>
<tr>
<td>Proteases inhibitors (cComplete, EDTA free)</td>
<td>Roche</td>
<td>Cat # 11873580001</td>
</tr>
<tr>
<td>Protein G agarose</td>
<td>Thermo Fisher</td>
<td>Cat # 15920</td>
</tr>
<tr>
<td>Puromycin</td>
<td>GIBCO</td>
<td>Cat # A11138-03</td>
</tr>
<tr>
<td>RPMI 1640</td>
<td>Sigma Aldrich</td>
<td>Cat # R8758</td>
</tr>
<tr>
<td>Sodium Acetate</td>
<td>Thermo Fisher</td>
<td>Cat # 10000500</td>
</tr>
</tbody>
</table>

(Continued on next page)
<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Fluoride</td>
<td>Sigma Aldrich</td>
<td>Cat # S1504-500G</td>
</tr>
<tr>
<td>Sodium Orthovanadate</td>
<td>New England Biolabs</td>
<td>Cat # 11873580001</td>
</tr>
<tr>
<td>Sodium Pyruvate</td>
<td>GIBCO</td>
<td>Cat # 11360070</td>
</tr>
<tr>
<td>Strep-Tactin Sepharose 50% suspension</td>
<td>IBA Lifesciences</td>
<td>Cat # 2-1201-010</td>
</tr>
<tr>
<td>Streptavidin Sepharose High Performance beads</td>
<td>GE Healthcare</td>
<td>Cat # 17-5113-01</td>
</tr>
<tr>
<td>Tetracycline-free FBS</td>
<td>Clontech</td>
<td>Cat # 631106</td>
</tr>
<tr>
<td>Trans-Blot Turbo Midi Nitrocellulose Transfer Packs</td>
<td>Biorad</td>
<td>Cat # 170-4159</td>
</tr>
<tr>
<td>Trans-Blot Turbo Mini Nitrocellulose Transfer Packs</td>
<td>Biorad</td>
<td>Cat # 170-4158</td>
</tr>
<tr>
<td>Trizma base</td>
<td>Sigma</td>
<td>Cat # T6066</td>
</tr>
<tr>
<td>Xba1</td>
<td>New England Biolabs</td>
<td>Cat # R0145</td>
</tr>
<tr>
<td>0.45 μm sterile filters</td>
<td>Sartorius Stedim</td>
<td>Cat # 1655-K</td>
</tr>
<tr>
<td>8 well chamber Glass μ-slide</td>
<td>Ibidi</td>
<td>Cat # 80821</td>
</tr>
<tr>
<td>96-well V-bottom plates</td>
<td>Thermo Fisher</td>
<td>Cat # 634-0009</td>
</tr>
</tbody>
</table>

### Critical commercial assays

- QiAprep Spin Midiprep Kit: QIAGEN, Cat # 27106
- QiAprep Spin Miniprep Kit: QIAGEN, Cat # 12243
- BP Clonase II kit: Thermo Fisher, Cat # 11791020
- LR Clonase II kit: Thermo Fisher, Cat # 11789020

### Experimental models: Cell lines

- Human: TCRβ−/CD8− Jurkat 31.13; (J13.31) [Alcover et al., 1990] N/A
- Human: TCRβ+ /CD8− Jurkat J76; (CD8− J76) [Heemskerk et al., 2003] N/A
- Human: TCRβ+ /CD8+ Jurkat J76;(J76) This study N/A
- Human: 1G4WT[J76 CD8−;CD8− J76 1G4 WT)] This study N/A
- Human: 1G4WT[A291]+J76 CD8−; (CD8− J76 1G4 A291) This study N/A
- Human: 1G4WT[A291]+J76 CD8+; (J76 1G4 [A291) This study N/A
- Human: 1G4WT[F291]+J76 CD8−; (CD8− J76 1G4 [F291) This study N/A
- Human: 1G4WT[L291]+J76 CD8−; (CD8− J76 1G4 [L291) This study N/A
- Human: 1G4WT[A293]+J76 CD8−; (CD8− J76 1G4 [A293) This study N/A
- Human: 1G4WT[A303]+J76 CD8−; (CD8− J76 1G4 [A303) This study N/A
- Human: 2H5WT[J76 CD8−;J76 CD8− 2H5 WT) This study N/A
- Human: 2H5WT[A291]+J76 CD8−;J76 CD8− 2H5 [A291) This study N/A
- Human: 1G4WTCD3−/−J76 CD8+; (J76-1G4WT−[KO) This study N/A
- Human: 1G4WTCD3−/−J76 CD8+ expressing CD3[WT; (J76-1G4WT−[KO expressing [WT) This study N/A
- Human: 1G4CD3−/−J76 CD8+ expressing CD3[WT; (J76-1G4WT−[KO expressing [WT) This study N/A
- Human: 1G4CD3−/−J76 CD8+ expressing CD3[WT; (J76-1G4WT−[KO expressing [WT) This study N/A
- Human: 1G4CD3−/−J76 CD8+ expressing CD3[WT; (J76-1G4WT−[KO expressing [WT) This study N/A

(Continued on next page)
**RESOURCE AVAILABILITY**

**Lead contact**
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Oreste Acuto (oreste.acuto@path.ox.ac.uk).

**Materials availability**
There are no restrictions on any data or materials presented in this paper. Requests for unique resources and reagents generated in this study should be directed to and will be fulfilled by the lead contact. Please see the [key resources table](#) for commercially available materials.

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human: 1G4 QM-α J76 CD8+; (QM-α)</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>Human: 868 J76 CD8+; (J76 868)</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>Human: 868 J76 CD8+; (CD8+ J76 868)</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>Human CD8+ primary T cell 1G4 wtc51</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>Human: 1G4 α/β TST expressing CD3ζ-TST (J76 1G4 ζ-TST)</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>Human: HEK293T</td>
<td>ATCC</td>
<td>Cat # CRL-3216</td>
</tr>
<tr>
<td>Human: Lenti-X293T</td>
<td>Clontech</td>
<td>Cat # 632180</td>
</tr>
<tr>
<td>Oligonucleotides</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>See Table S2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Recombinant DNA**

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>pDONR-221</td>
<td>Thermo Fisher scientific</td>
<td>Cat # 12536017</td>
</tr>
<tr>
<td>pEF3 FLAG</td>
<td>K. Nika, University of Oxford</td>
<td>N/A</td>
</tr>
<tr>
<td>pEF3 HA</td>
<td>K. Nika, University of Oxford</td>
<td>N/A</td>
</tr>
<tr>
<td>pEXPR-IBA103</td>
<td>IBA Lifesciences</td>
<td>Cat # 2-3503-000</td>
</tr>
<tr>
<td>pHr-CD8αα</td>
<td>A. Van Der Merwe, University of Oxford</td>
<td>N/A</td>
</tr>
<tr>
<td>pHr-SIN-BX-IRES-Emerald</td>
<td>V. Cerundolo, University of Oxford</td>
<td>N/A</td>
</tr>
<tr>
<td>pLIX-402</td>
<td>Addgene</td>
<td>Cat # 41394</td>
</tr>
<tr>
<td>pLEX_307</td>
<td>Addgene</td>
<td>Cat # 41392</td>
</tr>
<tr>
<td>psPAX2</td>
<td>Addgene</td>
<td>Cat # 12260</td>
</tr>
<tr>
<td>pVSV-G</td>
<td>Addgene</td>
<td>Cat # 14888</td>
</tr>
</tbody>
</table>

**Software and algorithms**

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>FlowJo</td>
<td>BD</td>
<td>N/A</td>
</tr>
<tr>
<td>GROMACS</td>
<td><a href="http://www.gromacs.org/">http://www.gromacs.org/</a></td>
<td>N/A</td>
</tr>
<tr>
<td>Image Studio</td>
<td>Li-COR Bioscience</td>
<td>N/A</td>
</tr>
<tr>
<td>Insight3</td>
<td>B. Huang, University of California, San Francisco</td>
<td>N/A</td>
</tr>
<tr>
<td>Jalview</td>
<td>Waterhouse et al., 2009</td>
<td>N/A</td>
</tr>
<tr>
<td>MATLAB software</td>
<td>S. Shelby and S. Veatch, University of Michigan</td>
<td>N/A</td>
</tr>
<tr>
<td>OriginPro 2017</td>
<td>OriginLab</td>
<td>N/A</td>
</tr>
<tr>
<td>Prism</td>
<td>GraphPad Software</td>
<td>N/A</td>
</tr>
<tr>
<td>PyMOL</td>
<td>Schrödinger LLC</td>
<td>N/A</td>
</tr>
<tr>
<td>SnapGene</td>
<td>GSL Biotech LLC</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Other**

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hi-Load 16/600 Superdex 200 pg Column</td>
<td>GE Healthcare</td>
<td>Cat # 28-9893-35</td>
</tr>
<tr>
<td>Superdex-200 Increase 5/150 GL Column</td>
<td>GE Healthcare</td>
<td>Cat # 28-9909-44</td>
</tr>
</tbody>
</table>
**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Cell lines**
Cell lines were maintained at 37°C with 5% CO₂ in a humidified incubator (Heraeus). Human embryonic kidney epithelial 293T cells HEK293T (ATCC CRL-3216) and Lenti-X293T (Clontech) cell lines were cultured in complete DMEM (Sigma Aldrich) supplemented with 15% fetal bovine serum (FBS). Jurkat-derived cell line variants 31.13 (Alcover et al., 1990) (abbreviated J31.13) and J76 (Heemskerk et al., 2003), which lack expression of TCRβ and TCRαβ respectively, were cultured in RPMI 1640 supplemented with 10% FBS. Key resources table lists all the above cell lines and those that were derived from J31.13 and J76 in this study. Cells were routinely tested and found negative for mycoplasma and are not STR profiled. Jurkat cell lines containing a tetracycline-inducible gene expression systems were maintained in RPMI 1640 supplemented with 10% tetracycline-negative FBS (Clontech).

**Primary T cells**
Primary CD8 T cells were obtained from HLA-A2/C0 healthy donor blood cones (NHS) by density gradient centrifugation and negative selection using EasySep Human CD8 T cell isolation kit (STEMCELL). Isolated T cells were rested overnight at 2 x 10⁶/ml in RPMI medium (Sigma) supplemented with 2 mM Glutamine, 1 mM Sodium Pyruvate, Non-essential AA, 50 μg/ml Kanamycin, 5% human serum (Sigma).

**METHOD DETAILS**

**DNA constructs and cloning**
All plasmid DNA was propagated in E. coli strains DH5α or Stbl3.

**Generation of 1G4 α and 1G4 β plasmids for transient transfections**
1G4 α and β sequences were amplified from total cDNA extracted (Roche cDNA extraction kit) from an established 1G4 expressing Jurkat cell line (Aleksic et al., 2010) with appropriate primers (see primers in Table S2) and cloned into pEF3 with a Flag- and HA-tag respectively.

**Site directed mutagenesis**
Single amino acid mutations in the 1G4 β chain were introduced using a modified QuikChange protocol (Agilent). Briefly, PCR primers were generated using the QuikChange open source software. PCR was carried out with an optimized protocol and the resulting product was purified using QiaQuick Gel purification kit (QIAGEN). A fraction of purified PCR was digested with DpnI for 2 h and used to transform Stbl3 E. coli (Invitrogen). DNA was extracted from colonies, analyzed by gel electrophoresis and sequenced (Source BioScience, UK).

**Generation of the self-cleavable 1G4 αβ construct (stable cell lines)**
A DNA construct was designed to obtain a single mRNA for β and α giving rise to a single polypeptide separated by the foot-and-mouth disease virus 2A (F2A) self-cleavable sequence (Ryan et al., 1991). This strategy should facilitate expression of similar amounts of β and α proteins. The aa sequence of the entire construct is provided in Table S1. See Figure S1A for a schematic of the construct. Constructs for Tet-inducible expression of 1G4 αβ, 2H5 αβ, ζ WT and mutants, affinity enhanced 1G4 (wtc51 and QM-α), ζ TST and constitutive 1G4 αβ and 868 TCR

To generate an inducible expression system for 1G4 αβWT and 1G4 αβWT/βA291, the sequence coding for the self-cleavable single polypeptide β-HA-F2A-α-FLAG was cloned into the doxycycline inducible Gateway cloning plasmid pLIX-402 (Addgene) following the manufacturer’s guidelines for Gateway cloning. Briefly, the DNA sequence containing the entire αβ sequence was PCR amplified from the constitutive expression plasmid pHR with primers containing the Gateway recombination sites (see primers for Gateway cloning in Table S2). Purified PCR products were inserted via the BP recombination reaction into the Gateway entry vector pDONR-221 (Thermo Fisher). After verification of successful recombination by automated sequencing (Source Bioscience, UK), the resulting entry clones were used for a LR recombination reaction to insert the sequence into the pLIX-402 destination vector (Addgene), which carries a tetracycline-inducible promoter for conditional expression of the gene of interest. Both BP and LR reactions were performed with BP and LR Clonase II kits (Thermo Fisher). To clone the high affinity TCRs (wtc51 and QM-α) and the entire panel of 1G4 and 2H5 β and γ constructs, synthetic DNA fragments coding for either self-cleavable single polypeptide 1G4 αβ (αβWT plus βWT or mutants βA291, βL291, βI291) or 2H5 WT and 2H5 βA291 or γWT and mutants γA38 and γA41 were purchased from GeneArt Gene Synthesis (Thermo Fisher). All DNA fragments contained consensus sequences for Gateway Cloning System and the αβ and γ constructs were introduced into the Gateway plasmid pLIX-402 for inducible expression, following the Gateway cloning protocol as described above. After cloning into the expression vectors, the coding sequences were verified by automated sequencing (Source BioScience, UK). To generate a twin-strep tagged (TST) γ containing cell line the sequence of γ was cloned, after XbaI/EcoRI digestion, into the plasmid pEXP103 IBA (IBA Lifesciences), to be fused with a TS-tag at the C terminus. The γTST sequence was subsequently amplified and cloned into pLIX-402 destination vector following the gateway procedure as described above. (See primers for
Gateway cloning in Table S2). To generate a constitutive expression system for 1G4 αβ and 868 αβ synthetic DNA fragments coding for either self-cleavable single polypeptide 1G4 αβ and 868 αβ were purchased from GeneArt Gene Synthesis and were introduced into the Gateway plasmid pLEX 307 (Addgene) for constitutive expression, following the Gateway cloning protocol as described above.

**CRISPR/Cas9-mediated ζ knock-out**

CRISPR/Cas9 mediated knock-out (KO) of ζ was achieved using the pX458 two component vector (Addgene) and the guide sequence CAGGGCACAGTTGCCGATTACAGG. J76 expressing CD8 and the single polypeptide 1G4 αβ were transiently transfected and CD3 negative cells were sorted. Efficient knock-out was verified by transient transfection of the proteins of interest and analysis of rescue by FACS analysis.

**TCR-CD3 expression**

**Transient expression of TCR-CD3**

J31.13 cells were grown to approximately 0.5 – 0.6 \( \times 10^5 \) cells, were counted, harvested (2 \( \times 10^6 \) cells per electroporation) and centrifuged at 1,200 rpm. The supernatant (conditioned medium) was collected, diluted with equal volume of RPMI containing 10% FBS and kept at 37°C in the incubator. Cells were washed twice in RPMI and re-suspended in 400 µL RPMI and placed in sterile Biorad GenePulser Cuvettes (0.4 cm) containing 2 µg of plasmid DNA per 10^6 cells. Constructs and mutant DNA were routinely purified from E. coli using QIAGEN迷你-或mid-prep kits (QIAGEN). Electroporation was performed with a Biorad GenePulser X-cell at 260 V, 1 pulse of 25 ms using the square root method. Cells were flushed out of the cuvette with 200 µL conditioned medium and placed at 37°C in the incubator until final use. Cells were usually assayed after 24 - 48 h and analyzed by flow cytometry for CD3 surface expression or for pErk in response to pMHC tetramer.

**Generation of stable cell lines**

For lentiviruses infection, recipient cells were cultured up to approximately 0.5 – 0.6 \( \times 10^5 \)/ml. Cells were washed once in RPMI, checked for viability, counted and adjusted to 10^6/ml in RPMI supplemented with 10% FBS (tetracycline-free (Tet) in the case of transduction with doxycycline-inducible plasmids) (GIBCO or Clontech) and 5 µg/ml of polybrene (Sigma). Cells were plated in 12-well (1 ml/well) or 6-wells plates (2 ml/well) and one aliquot of lentivirus was added (for preparation of lentiviruses see below). 24 h post-infection, cells were washed and re-suspended in RPMI 10% FBS (standard or Tet) followed by a centrifugation at 1,500 x g for 30 min at 4°C. The pellet containing an antibiotic selection marker, cells were cultured for an additional 24 h before starting selection with puromycin (1 µg/ml, GIBCO). With adequate lentivector concentration, cell mortality was relatively low.

For tetracycline-inducible cell lines, gene expression could be started after 72 h by adding 0.1 - 1 µg/ml of doxycycline hyclate (Sigma Aldrich). Cells were collected after approximately 16 h and tested for CD3 expression and signaling by flow cytometry.

**Primary T cells** were plated in 24-well (1 ml/well) at 1 \( \times 10^6 \)/ml and stimulated with human T-activator CD3/CD28 Dynabeads (Thermo Fisher Scientific) at 2:1 bead to T cell ratio in complete medium supplemented with 500 U/ml IL-2. After 48 h most of the medium was removed and replaced with fresh medium supplemented with 500 U/ml IL-2, containing 40 µL of concentrated lentiviral stock in presence of 5 µg/ml polybrene (Sigma). After 4 days the dynabeads were removed and 1G4 wtc51 positive cells were sorted after (9V-A2)+, PE staining. Sorted cells were kept in complete medium supplemented with 500 U/ml IL-2 and re-stimulated with human T-activator CD3/CD28 Dynabeads 12 days after the sorting.

**Production of lentiviral particles**

Lentiviruses were generated using the packaging cell lines HEK293T or Lenti-X293T. The culture medium was exchanged with RPMI with 10% FBS just prior to transfection. HEK293T or Lenti-X293T at 80% confluence were transfected using PEIpro (Polyplus) according to the manufacturer’s instructions or by a standard calcium-phosphate precipitation protocol. The packaging plasmids pVSVG and pSPAX2 were mixed with the lentivirus expression vectors containing the gene of interest. For the PEIpro transfection, PEIpro solution was added to the plasmids mix and immediately vortexed, left 15 min at room temperature (RT) and then added drop-wise to the cells by gently swirling the plate. For calcium-phosphate precipitation, cells were left 3 h with DNA-calcium-phosphate precipitate and the media replaced with complete DMEM with 15% FBS. Independently of the transfection protocol, supernatant containing lentiviral particles was collected after 48 h and filtered through a 0.45 µm sterile filter (Sartorius Stedim). Lentivirus supernatants were either used immediately or concentrated with PEG-it™ (SBI) concentration kit according to the manufacturer’s instruction. Briefly, lentiviral supernatants were mixed with Virus Precipitation Solution (SBI) to a final concentration of 1X Virus Precipitation Solution and incubated overnight at 4°C followed by a centrifugation at 1,500 x g for 30 min at 4°C. The pellet containing lentivirus particles was re-suspended in 1/100 of the volume of the original cell culture using cold RPMI. Aliquots were immediately frozen in cryogenic vials at - 80°C and stored until use. Aliquots of each lentivirus batch were routinely pre-tested by serial dilution titration. Frozen aliquots were thawed only once and used immediately with minimal loss of virus titer as determined by flow cytometry.

**Preparation of pMHC monomers and tetramers**

pMHC monomers were produced as described elsewhere (Altman and Davis, 2003) with some modifications. Human beta-2 microglobulin (β2 m) and the 1 - 278 segment of HLA-A*02:01 heavy chain with the Avitag at the C terminus were separately expressed in E. coli. Both proteins were recovered from inclusion bodies with Bug Buster protein extraction reagent (Millipore) supplemented with
lysozyme and benzonase (Millipore). For monomer refolding, HLA heavy chain and β2 m were added to refold buffer (100 mM Tris, 400 mM L-arginine hydrochloride, 2 mM EDTA, 5 mM reduced glutathione, 0.5 mM oxidised glutathione, 0.1 mM PMSF) supplemented with 0.5 mM urea and 10 µg/ml synthetic peptide (> 95% purity by HPLC) of either one the following variants of the NY-ESO-1 antigen (Aleksic et al., 2010) (SLLMWITQV, residues 157-165): 9V (SLLMWITQV, residues 157-165); 6V (SLLMWITQV, residues 157-165); 6I (SLYNTIATL, Cambridge Peptides Inc.) or the 6I (SLYNTIATL, Cambridge Peptides Inc.). Alternatively, His-streptavidin (Anti-mFab’ aggregates. Biotin-labeled UCHT1-Fab’ was diluted to a concentration of 0.3 mg/ml in PBS and 40 mM 18 kDa serum albumin (BSA) (Sigma) in PBS). After spinning, supernatants were removed and cell pellets re-suspended in 50 mM MALS) for sm-9V-A2 to further control for mono-dispersity and unique molecular mass in the peak.

Preparation of UCHT1-Fab’ fragment
A Fab’ fragment was prepared from the purified mAb UCHT1 (BioXCell). Briefly, UCHT1 was digested with Pepsin (Thermo Fisher) in 100 mM Sodium Acetate (Thermo Fisher) for 24 h at 37 °C on a rocking platform. The digest was incubated overnight at 4 °C on a rotating shaker with Protein G agarose (Thermo Fisher) to remove the Fc fragment. The resulting Fab was reduced with 2-Mercaptetoethylamine-HCl (MEA-HCl) (Thermo Fisher) for 90 min at 37 °C, according to the manufacturer’s instructions, to obtain the Fab’ fragment. MEA-HCl excess was removed using a Zeba Spin Desalting column (GE Healthcare) and the Fab’ fragment eluted in Phosphate Buffered Saline (PBS, Sigma) at pH 7.0. The UCHT1-Fab’ was conjugated to biotin using EZ-Link Maleimide-PEG2 biotin (Thermo Fisher) or to Alexa Fluor 647 or 488 using Alexa Fluor 647 C2 Maleimide and Alexa Fluor 488 C5 Maleimide respectively (Thermo Fisher). The Fab’ was mixed in 1:10 molar ratio with 2 mM EZ-Link Maleimide-PEG2 biotin or with Alexa Fluor 647 C2 Maleimide for 5 h with slight agitation on a rocking platform at RT. Reagent excess was removed using a Zeba Spin Desalting column. The biotin, Alexa Fluor 488 or Alexa Fluor 647-labeled UCHT1-Fab’ fragments were analyzed on a non-reduced 4 - 15% Mini-PROTEAN Precast protein gel (Bio-Rad) and stored in PBS at 4 °C. The biotin-labeled UCHT1-Fab’ was further analyzed by FPLC to detect formation of Fab’ aggregates. Biotin-labeled UCHT1-Fab’ was diluted to a concentration of 0.3 mg/ml in PBS and 40 µl were analyzed by size exclusion chromatography. The analysis was carried out using a Superdex 200 increase 5/150 GL column (GE Lifesciences) and the ÄKTA Pure system (GE Lifesciences). Fab’ was applied onto the column using a 40 µl loop at a flow rate of 100 µl/min. Isocratic elution with PBS occurred at 300 µl/min with a total elution volume of 3 ml.

Flow cytometry
General staining procedures
This section provides a description of the procedures used for antibody (Ab)-mediated cell staining for flow cytometry and data acquisition. Staining was performed in 96-well V-bottom plates (Thermo Fisher) and centrifugations carried out at 670 x g for 1 min in a plate centrifuge (Eppendorf Centrifuge 5810R or Thermo IEC CL30 Centrifuge). Care was taken to gently re-suspend cells after each centrifugation to avoid cell damage and/or death. To optimize the sensitivity of the flow cytometry-based assays, Abs used in this study were systematically titrated for staining of cells expressing or lacking the target antigen and the conditions showing the best signal-to-noise were chosen. Flow cytometry staining was routinely carried out in duplicates or triplicates. For cell surface staining, 0.1 x 10⁶ cells/sample were transferred into a 96-well V-bottom plate, washed once in 150 µL FACS buffer (0.5% bovine serum albumin (BSA) (Sigma) in PBS). After spinning, supernatants were removed and cell pellets re-suspended in 50 µL staining solution containing fluorescence-conjugated primary Ab (see Key resources table for a list of the Abs used in this study) diluted in FACS buffer and incubated for 20 min at RT or for 30 min at 4 °C, depending on the Ab used. After removal of the staining solution, samples were washed twice with 150 µL FACS buffer and flow cytometry data acquired immediately or cells were fixed with 150 µL pre-warmed fixation solution (BD Cytofix®, BD Biosciences) for 10 min at 37 °C. For staining of intracellular antigens, fixed samples were washed twice in 150 µL permeabilisation buffer (BD Perm/Wash I, BD Biosciences), re-suspended in 150 µL permeabilisation buffer and incubated at RT for 30 min. Permeabilised cells were stained in 50 µL permeabilisation buffer containing the desired Ab dilution. For fluorescent-conjugated primary Ab staining, samples were incubated at RT for 1 h (except for anti-pY142 CD3ε and anti-HA, which were incubated at 4 °C for 2 h). When fluorescent-conjugated secondary Abs were used, they were diluted in 50 µL permeabilisation buffer and added to cells for 20 min at RT. After each staining, cells were washed 3 times with 150 µL permeabilisation
buffer and once with 150 μL FACS buffer at the end of the staining procedure. When surface co-staining was included, it was performed prior to fixation as described above. Samples were left in FACS buffer for storage and acquisition and acquired on a CyAn ADP analyzer (Beckman Coulter) or BD LSR Fortessa X20 (BD Bioscience) as specified. Raw data was analyzed by FlowJo (FlowJo Software part of BD). Counts, percentages or median intensity fluorescence values (MFI) were extracted from FlowJo as excel files. Statistical analysis and non-linear regression were performed with Prism (GraphPad Software).

CellTrace violet labeling
Cells were washed once in PBS and adjusted to a final concentration of 10^6 cells/ml in pre-warmed PBS at 37°C. CellTrace violet (Thermo Fisher) or carrier control DMSO (Sigma) was added to reach the indicated staining concentration and cells were incubated at 37°C in the dark. After 20 min, samples were diluted 5-fold in complete medium and incubated for an additional 5 min at 37°C in the dark. After removal of the diluted staining solution, cells were re-suspended in complete medium, counted and cultured or mixed as indicated.

UCHT1-Fab’ fragment binding
J76 1G4 WT or β mutants were induced for TCR expression with doxycycline 1 μg/ml for 96 h. TCR-deficient J76 CD8^+ cells were used to evaluate the background. Cells were harvested and stained with AF488-conjugated UCHT1-Fab’ at the indicated dilutions in FACS buffer for 30 min at 4°C. After removing excess of UCHT1-Fab’, cells were fixed, permeabilised and intracellular staining was performed with Alexa647-conjugated anti-HA mAb (1:50) as described in the flow cytometry protocol section. Samples were acquired on CyAn ADP analyzer (Beckman Coulter). Raw data was analyzed in FlowJo and MFI of UCHT1-Fab’ binding in the TCRβ-HA positive population extracted as excel files. Further analysis and statistical tests were performed in Prism (GraphPad Software). MFI of UCHT1-Fab’ binding after background subtraction was plotted against the concentration of UCHT1-Fab’ and fitted with non-linear regression (One site - Specific binding).

pMHC-tetramer binding to cells for association and dissociation analysis
To measure the relative association rate of pMHC tetramers to WT and βA291 TCR, J76 CD8^+ 1G4 WT or βA291 cells were induced for TCR expression with 1 μg/ml doxycycline for 48 - 72 h. TCR-deficient J76 cells were used to evaluate binding background. Cells were labeled with 200 nM CellTrace violet (Thermo Fisher) or with carrier control DMSO (Sigma), mixed 1:1 and washed once before being re-suspended at 20 x 10^5/ml in RPMI, pre-warmed at 37°C. Cells were then distributed at 0.5 x 10^5 cells, 25 μl/well in a 96-well V-bottom plate (Eppendorf) and equilibrated at 37°C for 10 min in a Thermomixer C (Eppendorf). 1:2 dilution series of 2X (6V-A2)_β-PE were added to the wells to a final concentration of 400 to 3.125 nM as indicated in the plot. After 10 min binding, a 3-fold excess of fixation buffer (BD Cytofix) was added and samples fixed for 10 min at 37°C. Samples were permeabilised and stained intracellularly with anti-HA (1:50) to detect total TCRβ as described in Flow cytometry protocols. Raw data was analyzed in FlowJo and MFI of (6V-A2)_β-PE binding in the TCRβ-HA as for the binding assay. Samples were acquired on a CyAn ADP. Raw FACS data was analyzed in FlowJo (FlowJo Software) and MFI of (6V-A2)_β-PE binding and TCRβ-HA were extracted as excel files. Further analysis and statistical tests were performed in Prism (GraphPad Software). MFI of the (6V-A2)_β-PE binding was corrected for background, normalized for maximal binding (max. binding = 100%), plotted against the concentration of (6V-A2)_β-PE or against the time after initial binding and the curves were fitted by non-linear regression (Specific binding with Hill slope or Dissociation - One phase exponential decay).

TCR-CD3 expression efficiency
To evaluate the efficiency of TCR-CD3 surface expression, J76 CD8^+ 1G4 (or 2H5) WT or β mutant cells were induced for TCR expression with 1 μg/ml doxycycline overnight at 0.3 x 10^6 cells/ml. Cells were incubated with 50 nM CellTrace violet or carrier control DMSO (Sigma), mixed in a 1:1 ratio and stained for surface CD3 and intracellular TCRβ-HA, using UCHT1 AF647-conjugated Fab’ and AF488-conjugated anti-HA mAb respectively, as described in Flow cytometry procedures. J76 CD8^+ 1G4 (or 2H5) WT or β mutants, non-induced with doxycycline were used to evaluate binding background. Cells were analyzed on a BD LSR Fortessa X20 flow cytometer (BD Biosciences) and acquired data was analyzed with FlowJo FACS analysis software v10.0 (Tree Star, BD). 2D plots of TCRβ-HA versus CD3 were obtained and gates for different levels of TCRβ-HA (low, medium and high) were applied. The MFI ± SD of CD3 and TCRβ-HA was extracted within each gate and normalized to the WT in the corresponding gate. Statistical analysis using unpaired t test was performed using Prism (GraphPad Software). MFI ± SD of TCRβ-HA for 1G4 WT and β mutants in those bins was not statistically significant (ns). The same procedure was used to evaluate the efficiency of TCR-CD3 surface expression in J76 CD8^+ 1G4 KO expressing WT and μ mutations (ζA38, ζA41).

pMHC-tetramer stimulation for pErk or pζ-dose-response
To measure proximal signaling in response to stimulation with pMHC, J76 CD8^+ or CD8^+ 1G4 (or 2H5) WT or mutant cells were induced for TCR expression with doxycycline (dox) overnight at 0.3 x 10^6 cells/ml. In all pMHC-tetramer stimulations for pErk, J76 CD8^+ or CD8^+ 1G4 WT (or 2H5 WT) were induced for TCR expression with 0.8 - 0.2 μg/ml of dox whereas β (or ζ) mutants were induced with 1 μg/ml. Different doses of doxycycline for 1G4 WT (or 2H5 WT) and β (or ζ) mutants were used in order to achieve
same TCR-CD3 surface expression and to simplify computation of signaling outputs and eliminate potential errors arising from normalizing for unequal (6V-A2)_4 binding. Cells were then labeled with 50 nM CellTrace violet (Thermo Fisher) or with carrier control DMSO (Sigma). CellTrace labeling did not interfere with proximal signaling events. To measure TCR surface expression a surface staining with AF647-conjugated UCHT1-Fab' fragment was performed according to the protocol described in Flow cytometry procedures before the stimulation assay. For this, labeled and unlabelled cells were mixed 1:1 and washed once before being re-suspended at 20 \times 10^6/ml in RPMI without FBS pre-warmed at 37 °C. Cells were then distributed at 0.5 \times 10^6 cells/well (25 \mu l) in a 96-well V-bottom plate (Eppendorf) and equilibrated at 37 °C for 10 min in a ThermoMixer C (Eppendorf). 1:2 dilution series of 2X (6V-A2)_4-PE or (MART-1-A2)_4-PE were added directly to the wells to a final concentration of 600 to 0.78 nM and 50 to 0.05 nM, respectively. After stimulation (p\_er: 60 s, pErk: 180 s) an excess of fixation buffer (BD Cytofix) was added and samples fixed for 10 min at 37 °C. Samples were permeablised and stained intracellularly with AF647-conjugated anti-pErk (1:50) or with AF647-conjugated anti-pY142\_C (1:5) as described in Flow cytometry procedures. Samples were acquired on a CyAn ADP (Beckman Coulter) or BD LSR Fortessa X20 (BD Bioscience) as specified. Raw data was analyzed by FlowJo (FlowJo software, part of BD) and MFIs were extracted from FlowJo as excel files. Further analysis and statistical tests were performed with Prism (GraphPad Software). For p\_er dose-response the background subtracted MFIs of p\_er were plotted against the background subtracted MFI of tetramer (6V-A2)_4-PE binding and fitted by non-linear regression ([Agonist] versus response - three parameters). The background subtracted values of MFIs of p\_er with the highest dose of (6V-A2)_4-PE (400 nM) were normalized to WT or left as pairs and tested for significance with a t test (paired or unpaired respectively). For pErk-dose-responses, pErk MFIs were background subtracted and plotted against the dose of (6V-A2)_4-PE or (MART-1-A2)_4-PE and fitted by non-linear regression ([Agonist] versus response - Variable slope (four parameters) or [Agonist] versus response - three parameters) or fitted to a minimal model of kinetic proofreading signaling (see Mathematical modeling section). In both non-linear regression fits, no constraints were imposed and the expected best-fit values of maximum pErk for WT and mutant were analyzed for significance with the F-test. The same procedure was used to evaluate max. pErk response upon (6V-A2)_4-PE titration, in J76 CD8\_C KO expressing WT and \_mutants (A38, \_A41).

**PMA stimulation**

To evaluate maximal pErk potential of J76 CD8\_C 1G4 WT or \_A291, cells were labeled with 50 nM CellTrace violet (Thermo Fisher) or with carrier control DMSO (Sigma), mixed 1:1 and washed once before being re-suspended at 20 \times 10^6/ml in RPMI without FBS pre-warmed at 37 °C. Cells were then distributed at 0.5 \times 10^6 cells/well (25 \mu l) in a 96-well V-bottom plate (Eppendorf) and equilibrated at 37 °C for 10 min in a ThermoMixer C (Eppendorf). 1:2 dilution of 2X PMA (Phorbol 12-myristate 13-acetate, Sigma) and Ionomycin (Sigma) was added directly to the wells to a final concentration of 66.6 ng/ml and 2 \mu g/ml, respectively. After stimulation (180 s) an excess of fixation buffer (BD Cytofix) was added and samples fixed for 10 min at 37 °C. Samples were permeablised and stained intracellularly with AF647-conjugated anti-pErk (1:50) according to the protocol described above. Raw data was analyzed by FlowJo (FlowJo software, part of BD) and MFIs were extracted from FlowJo as excel files. Further analysis and statistical test were performed with Prism (GraphPad Software). The background subtracted values of MFIs of pErk for WT and \_A291 were exported and mean values of each experiment, measured in triplicates, were normalized to WT. Statistical significance was tested by unpaired t test using Prism (GraphPad Software).

**Basal \_C-phosphorylation**

J76 CD8\_C 1G4 WT or \_A291 cells were induced for TCR expression with 1 \mu g/ml doxycycline at 0.3 \times 10^6 cells/ml. Cells were harvested at 24, 48, 72 or 96 h and processed immediately for FACS analysis of CD3 surface expression or intracellular p\_C according to the protocol described in Flow cytometry procedures. As staining for CD3 surface expression with an anti-CD3\_C: induced signaling even when carried out at 4 °C using precooled solutions, samples were split in two and one part was stained for surface CD3 at 4 °C while the other part was fixed at 37 °C, permeablised and analyzed for basal p\_C. Samples were acquired on a CyAn ADP (Beckman Coulter). Raw data was analyzed by FlowJo (FlowJo software, part of BD) and MFIs were extracted from FlowJo as excel files. Further analysis and statistical tests were performed with Prism (GraphPad Software). p\_C MFI was normalized to CD3 MFI (p\_C/CD3), mean values of each experiment were normalized to WT or left as pairs and significance was tested by t test (unpaired or paired respectively).

**Sm-pMHC binding to cells**

To detect non-specific adsorption of sm-pMHC onto J76 cell membrane during the stimulation assay (see Soluble monovalent-pMHC stimulation section) CD8-deficient wtc51 J76 were induced or not for TCR expression with 1 \mu g/ml doxycycline for 48 h, labeled with 50 nM CellTrace violet (Thermo Fisher) or with carrier control DMSO (Sigma), mixed 1:1 and washed once before being re-suspended at 10 \times 10^6 in 125 \mu l of pre-warmed RPMI at 37 °C. Cells were then distributed in a 96-well V-bottom plate (Eppendorf) and equilibrated at 37 °C for 10 min in a ThermoMixer C (Eppendorf) under constant shaking (500 rpm). Dilution series of 2X sm-9V-A2 were added directly to the wells to a final concentration of 400 to 0.2 nM as indicated in the plot. After 5 min of binding, samples were rapidly centrifuged at 4 °C, washed with 100 \mu l of ice-cold FACS-buffer and stained with APC-conjugated anti-HLA-A2 (1:100) for 20 min on ice to detect sm-9V-A2 binding to cells as described in Flow cytometry protocols. Samples were acquired on BD LSR Fortessa X20 (BD Bioscience). Raw FACS data for TCR-deficient and TCR-efficient J76 were analyzed in FlowJo (FlowJo Software) and MFI of APC-anti-HLA-A2 were extracted as excel files. Further analysis and statistical tests were performed in Prism (GraphPad Software). The MFI of the APC-anti-HLA-A2 binding was corrected for background, plotted against the concentration of sm-9V-A2 and the curves were fitted by non-linear regression.
Mathematical modeling
To fit the tetramer binding data, we used an effective 1:1 binding model:

\[ C = \frac{B_{\text{max}} \cdot |\text{Tetramer}|}{K_d + |\text{Tetramer}|} \]

where \( B_{\text{max}} \) is the maximum binding and \( K_d \) is an effective binding constant. We found that this model was able to fit both the WT and mutant TCR data. Importantly, we found that a single value of \( K_d \) was sufficient to fit both dataset or equivalently, we found no evidence to reject the null hypothesis that tetramer binding was identical to both (F-test, \( p = 0.066 \)).

To fit the pErk data, we coupled the binding model to a minimal model of kinetic proofreading signaling (Dushek et al., 2011; McKeithan, 1995)

\[ Y = \frac{\frac{|\text{Tetramer}|}{K_d + |\text{Tetramer}|}}{(kp + k_{\text{off}})^N} \]

where the first term determines tetramer occupancy (fraction between 0 and 1) and the second term determines the probability of signaling, \( k_p \) the forward rate of proofreading, \( N \) the number of steps, and \( k_{\text{off}} \) the unbinding rate.

Given that we found no evidence for a difference in binding (see above), we asked whether a difference in the proofreading rate (\( k_p \)) can explain the difference in the pErk data. To do this, we simultaneously fit both the WT and mutant TCR pErk data to the mathematical model with a different value of \( k_p \) for each TCR. As above, we fit a single value of \( K_d \) for both datasets and in this model, we fixed the value of \( K_d \) to the experimentally determined value (0.85 s\(^{-1}\); Aleksic et al., 2010) and fixed the value of \( N \) to the recently reported value (Tischer and Weiner, 2019; Yousefi et al., 2019). This is reasonable since we do not expect the TCR mutation to alter the number of steps.

We found that this model was able to produce an excellent fit to the data. Importantly, we found that a single value of \( k_p \) could not explain the pErk data or equivalently, we had sufficient evidence to reject the null hypothesis that a single value of \( k_p \) could explain the data (F-test, \( p < 0.0001 \)).

Biochemical analysis of the TCR-CD3 complex
SDS-PAGE, immunoblotting and quantitation
SDS-polyacrylamide gel electrophoresis (PAGE) was performed using the protein electrophoresis system from Bio-Rad (Bio-Rad) according to the manufacturer’s instructions. Custom-made 15% polyacrylamide gels were used and proteins separated at 100 V in TGS (Tris Glycine SDS) running buffer (Bio-Rad). Separated proteins were transferred onto nitrocellulose membranes (Trans-blot Turbo Transfer Pack, Bio-Rad) using the Trans-blot turbo transfer system (Bio-Rad). As a routine, the High-MW protocol (25 V, 1 A, 30 min) were used for the transfer. Membranes were saturated in blocking buffer at RT in the dark. The membrane was then washed twice for 10 min with wash buffer (TBS-T) and once with wash buffer without cold PBS. The cell pellet was lysed with 150 \( \mu \)L of ice-cold lysis buffer (150 mM NaCl, 20 mM Tris, pH 8.0 containing 0.5 or the indicated % of n-Dodecyl \( \beta \)-D-maltoside (DDM) (Millipore), 1X protease inhibitors (cComplete, EDTA free, Roche), 1 mM Sodium Orthovanadate (NEB), 10 mM Sodium Fluoride (Sigma) and 25 U/ml Benzonase Nuclease (Millipore) and incubated 30 min on ice. 0.5% DDM was chosen as it is the highest concentration of detergent compatible with maximal recovery of CD3 \( \varepsilon \) and \( \zeta \) associated with \( \alpha \beta \), in contrast, increasing concentration of DDM from 1% to 4% gradually decreased CD3 recovery, affecting \( \zeta \) more than \( \varepsilon \) (Figure S2A and data not shown). These data agreed with the recent cryo-EM structure (Dong et al., 2019) that shows \( \zeta \zeta \) to be the dimer most loosely associated to the rest of the complex. lysates were centrifuged at 10 min at 16,100 x g at 4°C and 15 \( \mu \)L of the post nuclear supernatant were saved for input control. The rest of the supernatant was transferred in a new tube containing 10 \( \mu \)L of anti-HA-conjugated agarose beads (Sigma) pre-washed 3 times with 1 mL of lysis buffer. One sample was transferred to a tube containing anti-HA-conjugated agarose beads pre-washed and pre-saturated for 2 h at 4°C under constant rotation with 50 \( \mu \)g/mL of HA peptide (Sigma), to assess background. Protein complexes were pulled down by incubating the supernatant and the anti-HA-conjugated agarose beads for 1 h at 4°C under constant rotation. Beads were centrifuged for 30 s at 2,500 x g and washed 3 times with 1 mL of ice-cold lysis buffer. After the last wash, the supernatant was carefully removed and the beads re-suspended in 20 \( \mu \)L 1X NuPAGE LDS Sample Buffer (Invitrogen) containing or not (see below) 1X NuPAGE Sample Reducing Agent (Invitrogen) and incubated at 70°C for 10 min. After cooling, beads were centrifuged for 30 s at 2,500 x g and the supernatant was
collected in a fresh tube, loaded on a 15% polyacrylamide gel at 4 °C and processed as described above (SDS-PAGE, immunoblotting and quantitation). The results were analyzed and presented as follow: for each sample, the background subtracted signals of ε, γ, δ and ζ were normalized to β and the obtained ratios (ε/β, γ/β, δ/β and ζ/β) were normalized to WT. Statistical unpaired t test analysis was performed using Prism (GraphPad Software). To evaluate γε and δε recovery to αβ, the supernatant from a single pull down was split in two, loaded in duplicates on a 15% polyacrylamide gel and immunoblotted for either β (HA), ε and γ or β (HA), δ, ε and ζ. Moreover, to minimize the interference of the IgG light chain of the anti-HA, used to pull down β, with the detection of γ and ε (molecular weight 20 - 25 kDa), at the end of the procedure described above, the beads were re-suspended in 20 µL 1X NuPAGE LDS Sample Buffer (Invitrogen) without adding reducing agent, but rather adding lodoacetamide (Sigma) to a final concentration of 20 mM, an alklylation agent used to block thiols of proteins. Iodoacetamide was present in all the buffers used in this specific pull down (lysis buffer and sample buffer).

For endoglycosidase H (endo H) treatment, protein complexes were eluted by re-suspending the beads in 22 µL of lysis buffer containing 1X Glycoprotein Denaturing Buffer (NEB) and incubating at 100 °C for 10 min. Beads were centrifuged for 30 s at 2,500 x g, the supernatant was collected, divided in two fresh tubes and 1X buffer 3 (NEB) was added in presence or not of endo H (750 U) for 1 h at 37 °C. Samples were then incubated at 70 °C for 10 min with 1X NuPAGE LDS Sample Buffer (Invitrogen) containing 1X NuPAGE Sample Reducing Agent (Invitrogen) and loaded on a 15% polyacrylamide gel at 4 °C and processed as described above (SDS-PAGE, immunoblotting and quantitation).

**TST pull-down**

J76 CD8+ 1G4 CKO expressing inducible TST were treated with 1 µg/ml doxycycline overnight, counted and washed once with 150 µL of ice-cold PBS. Pellets of 10 × 10^6 cells were lysed with 150 µL ice-cold lysis buffer (150 mM NaCl, 20 mM Tris, pH 8.0 containing 0.5% n-Dodecyl β-D-maltoside (DDM) (Millipore), 1X proteases inhibitors (complete, EDTA free, Roche), 1 mM Sodium Orthovanadate (NEB), 10 mM Sodium Fluoride (Sigma) and 25 U/ml Benzonase Nuclease (Millipore) and incubated on ice for 10 min. Lysates were centrifuged for 10 min at 16,100 x g at 4 °C and 15 µL of the post nuclear supernatant was collected as a control for total input. The rest of the supernatant was transferred into a fresh tube containing 10 µL Strep-Tactin Sepharose beads (IBA Lifesciences) pre-washed with lysis buffer and incubated for 30 min at 4 °C under constant rotation. Alternatively, the supernatant was incubated 30 min at 4 °C with anti-HA-conjugated agarose beads (Sigma). One sample was transferred to a tube containing Strep-Tactin beads or anti-HA-conjugated agarose beads pre-washed and pre-saturated for 2 h at 4 °C under constant rotation with 50 mM bortn or 50 µg/mL of HA peptide respectively, to assesse background. Beads were centrifuged for 30 s at 2,500 x g and washed 3 times with 1 mL of ice-cold lysis buffer. After the last wash, the supernatant was carefully removed and the beads re-suspended in 20 µL 1X NuPAGE LDS Sample Buffer (Invitrogen) containing 1X NuPAGE Sample Reducing Agent (Invitrogen) and incubated at 70 °C for 10 min. After cooling, beads were centrifuged for 30 s at 2,500 x g and the supernatant was collected in a fresh tube before being separated on a 15% polyacrylamide gel at 4 °C. Quantitative immunoblotting with anti-HA and anti-ζ mAbs were used to identify the β isoform interacting with ζ among the three identified in the total β pull-down performed using anti-HA-conjugated agarose beads.

**Ligand-induced TCR-CD3 quaternary structure changes**

Resting or pMHC-stimulated TCR-CD3

The structural integrity of the TCR-CD3 complex upon (9V-A2) or at 0 °C was evaluated for the following assay. J76 CD8+ or CD8- cells expressing inducible TCR wtc51 were treated with 1 µg/ml doxycycline overnight, counted and washed once with 150 µL of ice-cold PBS. Cells were re-suspended at 10 × 10^6/150 µL in the same medium and pre-incubated for 10 min at 37 °C in a ThermoMixer C (Eppendorf) under constant shaking (500 rpm) or 20 min on ice. (9V-A2) obtained using a His-tagged streptavidin (His-SA) (100 nM), sm-9V-A2 (200 nM) or RPMI alone was added to the cells for 5 min at 37 °C or on ice. After ligand binding, the samples were immediately centrifuged 30 s at 800 x g and rapidly washed once with 150 µL of ice-cold PBS. For Lck inhibition, cells were pre-treated with 5 µM A770041 (Axon) at 37 °C for 20 min prior to stimulation and 5 µM A770041 was kept during the binding. Cell pellets were lysed with 150 µL ice-cold lysis buffer (300 mM NaCl, 20 mM Tris, pH 8.0 containing 0.5% n-Dodecyl β-D-maltoside (DDM) (Millipore), 1X protease inhibitors (complete, EDTA free, Roche), 1 mM Sodium Orthovanadate (NEB), 10 mM Sodium Fluoride (Sigma) and 25 U/ml Benzonase Nuclease (Millipore) and incubated on ice for 5 min. Lysates were centrifuged for 5 min at 16,100 x g at 4 °C and 15 µL of the post nuclear supernatant was collected as a control for total input. The rest of the supernatant was incubated 5 min on ice with 1 µg of His-tagged streptavidin (sm-9V-A2 engaged samples) or transferred directly into a fresh tube containing 10 µL HisPur Cobalt Resin (Thermo Fisher) ((9V-A2) engaged samples) or 10 µL anti-HA-conjugated agarose beads (Sigma) (non-stimulated samples). Pre-washed with lysis buffer and incubated for 15 min and 30 min respectively at 4 °C under constant rotation. To assess background, one sample was transferred to HisPur Cobalt beads or anti-HA-conjugated agarose beads pre-washed and pre-saturated at 4 °C for 2 h under constant rotation with 300 mM Imidazole or 50 µg/ml of HA peptide respectively. Beads were centrifuged for 30 s at 2,500 x g and washed 3 times with 1 mL of ice-cold lysis buffer. After the last wash, the supernatant was carefully removed and the beads re-suspended in 20 µL 1X NuPAGE LDS Sample Buffer (Invitrogen) without reducing agent and incubated at 80 °C for 5 min. After cooling, beads were centrifuged for 30 s at 2,500 x g and the supernatant was collected in a fresh tube and incubated at 80 °C for 5 min with 1X NuPAGE Sample Reducing Agent (Invitrogen). Samples were separated on a 15% polyacrylamide gel at 4 °C and processed as described above (SDS-PAGE, immunoblotting and quantitation). Quantitative immunoblotting with anti-HA and anti-ζ mAbs were used to evaluate the amount of β and ζ.
pulled-down in each condition. The amount of ε extracted at steady state was normalized to a specific β isoform (β2) that we proved to be the only one able to interact with the ε chain (for details see in TST pull down) and that corresponds to the only detectable isoform in (9V-A2)ε-engaged receptor pull downs (for schematic of the procedure see Figures S6A and S7A). The value for ε/β2 ratio from non-stimulated samples was set equal to one. This value represented the recovery of intact TCR-CD3 complex and was compared to ε/β2 from (9V-A2)ε stimulated samples. Statistical analysis using unpaired t test was performed using Prism (GraphPad Software).

To isolate sm-9V-A2-engaged wt51 with monomeric avidin agarose beads (Thermo), cells were incubated with sm-9V-A2 (200 nM) or RPMI alone for 5 min at 37°C. After ligand binding, the samples were lysed as described above and the post-nuclear supernatant was incubated with monomeric avidin beads for 30 min at 4°C under constant rotation.

For primary CD8 T cells expressing constitutive TCR wt51, cells were incubated for 5 min at 37°C with (9V-A2)ε obtained using a His-tagged streptavidin (His-SA) (40 nM), 9V-A2 (400 nM) or RPMI alone. Lysis was performed in presence of 30 mM imidazole and this concentration was maintained during the following washes.

Isolation of (6l-A2)ε and sm-6l-A2 engaged receptors in J76 CD8ε cells expressing 868 TCR (Kd = 50 nM) was performed as described above with little variations. Cells were incubated with (6l-A2)ε obtained using a His-tagged streptavidin (His-SA) (40 nM), sm-6l-A2 (400 nM) or RPMI alone for 5 min at 37°C. Lysis was performed in the presence of 30 mM imidazole and this concentration was maintained during the following washes.

To have a comparable amount of β detected by immunoblotting in non-stimulated samples and (6l-A2)ε and sm-6l-A2 engaged samples, only 1/3 of the elution from non-stimulated samples was loaded on the gel.

Isolation of (9V-A2)ε engaged receptors in J76 CD8ε cells expressing inducible QM-ε TCR (Kd = 140 nM) was performed as described above with little variations. Cells were incubated with (9V-A2)ε obtained using a His-tagged streptavidin (His-SA) (333 nM), or RPMI alone for 5 min at 37°C. Lysis was performed in the presence of 30 mM imidazole and this concentration was maintained during the following washes. Elution was performed by incubating the beads at 4°C for 15 min with 15 μL of lysis buffer containing 300 mM imidazole. Beads were then centrifuged for 30 s at 2500 x g and the supernatant was collected in a fresh tube and incubated at 80°C for 5 min with 1X NuPAGE LDS Sample Buffer containing 1X NuPAGE Sample Reducing Agent (Invitrogen).

To have a comparable amount of β detected by immunoblotting in non-stimulated samples and (9V-A2)ε engaged samples, only 1/40 of the elution from non-stimulated samples was loaded on the gel.

**Soluble monovalent-pMHC stimulation**

Intracellular triggering upon soluble monovalent agonist (sm-pMHC) binding was evaluated by pErk activation, according to the following procedure. J76 CD8ε or CD8ε- cells expressing 868 or wtc51 TCRs (the latter induced for TCR-CD3 expression with 1 μg/ml doxycycline for 48 h) were counted and washed once with RPMI without FBS. Cells were re-suspended at 10 x 10^6/125 μL in the same medium and pre-incubated for 10 min at 37°C in a ThermoMixer C (Eppendorf) under constant shaking (500 rpm). For Lck inhibition, cells were pre-treated with 5 μM A770041 (Axon) at 37°C for 15 min prior to stimulation and 5 μM A770041 was kept during the binding. Tetramers (pMHC25,25 nM), sm-pMHC (100 nM) or RPMI alone were added to the cells for 5 min at 37°C. After ligand binding, samples were immediately boiled for 10 min at 95°C by adding pre-warmed 2X NuPAGE LDS Sample Buffer (Invitrogen) containing 2X NuPAGE Sample Reducing Agent (Invitrogen) to instantly stop the reaction. Cell lysates were let cool down and 25 U of Benzonase Nuclease (Millipore) were added every 15 min for 4 times to allow a complete DNA/RNA digestion. Lysates were centrifuged for 15 min at 16,100 x g at 4°C and supernatant was collected in a fresh tube before being separated on a 15% polyacrylamide gel. Quantitative immunoblotting with anti-pErk and anti-actin was used to evaluate the amount of Erk phosphorylation (for details, see SDS-PAGE, immunoblotting and quantitation). The value for pErk (background/actin ratio from non-stimulated samples was set equal to one. Statistical analysis using unpaired t test was performed using Prism (GraphPad Software).

To exclude that the observed signaling (pErk) was the consequence of surface cell-to-cell ligand cross-presentation, we used the above protocol (also used for the evaluation of sm-pMHC binding by FACS, see sm-pMHC binding to cells section) with cells expressing or not TCR. Briefly, CD8-deficient wt51 J76 not induced for TCR expression were counted, washed once with RPMI, re-suspended at 10 x 10^6/125 μL in the same medium and pre-incubated for 10 min at 37°C in a ThermoMixer C (Eppendorf) under constant shaking (500 rpm). Sm-9V-A2 (200 nM) or RPMI alone was added to the cells for 5 min at 37°C, rapidly washed with ice-cold RPMI (to minimize unbinding), re-suspended in pre-warmed RPMI at 10 x 10^6/125 μL and added to an equal amount of dox-induced CD8-deficient wtc51 J76 for 5 min at 37°C. After ligand binding cells were immediately boiled for 10 min at 95°C by adding pre-warmed 2X NuPAGE LDS Sample Buffer (Invitrogen) containing 2X NuPAGE Sample Reducing Agent (Invitrogen) to instantly stop the reaction and cell lysates were analysed as described above.

**UCHT1-Fabε or UCHT1 Ab-engaged TCR-CD3**

The structural integrity of the TCR-CD3 complex upon agonist stimulation of intact cells at physiological temperature or at 0°C was evaluated by the following assay. The anti-CD3ε mAb UCHT1 was used as a potent agonist of TCR-CD3 and its Fabε as the non-agonist control that binds to the same determinant. J76 CD8ε cells stably expressing 1G4 TCR were counted and washed once with RPMI without FBS. Cells were re-suspended at 10 x 10^6/150 μL in the same medium and pre-incubated for 10 min at 37°C in a ThermoMixer C (Eppendorf) under constant shaking (500 rpm) or for 20 min on ice. Mono-biotinylated Fabε of UCHT1 mAb (0.72 μg) or biotinylated UCHT1 intact mAb (2 μg) (BioLegend) was added to the cells for 5 min at 37°C or on ice. These doses...
of anti-CD3ε ligands that corresponded to approximately the same molarity were proven to pull-down similar amounts of TCR-CD3 complex, as detected by ε immunoblot. One sample was left untreated as negative control. After ligand binding, the samples were immediately centrifuged 30 s at 800 x g and rapidly washed once with 150 µL of ice-cold PBS. For Lck inhibition, cells were pretreated with 5 µM A770041 (Axon) at 37 °C for 20 min prior to binding of Fab’ UCHT1 or UCHT1 mAb and 5 µM A770041 was kept during the binding. Cell pellets were lysed with 150 µL ice-cold lysis buffer (150 mM NaCl, 20 mM Tris, pH 8.0 containing 0.5% n-Dodecyl β-D-maltoside (DDM) (Millipore), 1X proteases inhibitors (Complete, EDTA free, Roche), 1 mM Sodium Orthovanadate (NEB), 10 mM Sodium Fluoride (Sigma) and 25 U/ml Benzonase Nuclease (Millipore) and incubated on ice for 30 min. Lysates were centrifuged for 10 min at 16,100 x g at 4 °C and 15 µL of the post nuclear supernatant was collected as a control for total input. The rest of the supernatant was transferred into a fresh tube containing 10 µL Streptavidin Sepharose High Performance beads (GE Healthcare) pre-washed with lysis buffer and incubated for 1 h at 4 °C under constant rotation. Beads were centrifuged for 30 s at 2,500 x g and washed 3 times with 1 mL of ice-cold lysis buffer. After the last wash, the supernatant was carefully removed and the beads re-suspended in 20 µL 1X NuPAGE LDS Sample Buffer (Invitrogen) containing 1X NuPAGE Sample Reducing Agent (Invitrogen) and incubated at 70 °C for 10 min. After cooling, beads were centrifuged for 30 s at 2,500 x g and the supernatant was collected in a fresh tube before being separated on a 15% polyacrylamide gel. Quantitative immunoblot with anti-ε, anti-HA and anti-ζ mAbs was used to evaluate the amount of ε, β and ζ, respectively, pulled-down after each stimulatory condition (for details, see SDS-PAGE, immunoblotting and quantitation). The recovery of ε was assumed to be invariant in both the stimulatory (UCHT1 mAb) and non-stimulatory (UCHT1-Fab’) condition and was used for the normalization of the amounts of the other subunits in each pull-down. Therefore, the values for β/ε and ζ/ε ratios obtained from UCHT1-Fab’ engaged TCR-CD3 were set equal to one. These values represented the recovery of intact TCR-CD3 complex and were compared to the same ratios from UCHT1 stimulated samples. Statistical analysis using unpaired t test was performed using Prism (GraphPad Software).

Microscopy
dSTORM imaging and analysis
Prior to dSTORM imaging, cells were plated on glass µ-slide 8-wells chamber (Ibidi) coated with recombinant human ICAM-1 protein (R&D Systems) at 2.5 µg/ml concentration. Cells were incubated for 15 minutes at 37 °C followed by fixation for 30 min with 4% PFA at RT. Cells were blocked with 5% BSA in PBS for 1 h followed by incubation with an anti-CD3 primary antibody directly conjugated with Alexa Fluor 647 (BioLegend) for 1 h at RT. Cells were washed three times with PBS and post-fixed with 4% PFA for 5 min before imaging. Cysteamine based dSTORM imaging buffer was used to perform the single molecule localization experiments with the following composition: 100 mM Cysteamine MEA (Sigma Aldrich), 5% Glucose (Sigma Aldrich), 1% Glox (0.5 mg/mL glucose oxidase, 40 mg/mL catalase (Sigma Aldrich)) dissolved in 1X PBS. dSTORM imaging of CD3 was performed by using a 150 x 1.45-NA oil-immersion objective in TIRF mode (TIRF; Olympus). Laser light of 642 nm was used to excite the Alexa Fluor 647 dye and switch it to the dark state. An additional 405 nm laser light was used to reactivate the Alexa Fluor 647 fluorescence. The emitted light from Alexa Fluor 647 was collected by the same objective and imaged by an EMCCD camera (Evolve Delta; Photometrics) at a frame rate of 10 ms per frame. A maximum of 5,000 frames per condition were acquired. dSTORM images were analyzed and rendered as previously described (Bates et al., 2007; Huang et al., 2008) using a custom-written software (Insight3, provided by B. Huang, University of California, San Francisco). Peaks in single-molecule images were identified based on a threshold and fit to a simple Gaussian to determine the x and y positions. Only localizations with photon count > 400 photons were included, and localizations that appeared within one pixel in five consecutive frames were merged together and fitted as one localization. The final images were rendered by representing the x and y positions of the localizations as a Gaussian with a width that corresponds to the determined localization precision. Sample drift during acquisition was calculated and subtracted by reconstructing dSTORM images from subsets of frames (500 frames) and correlating these images to a reference frame (the initial time segment).

Pair auto-correlation analysis
Pair auto-correlation analysis is independent of the number of localizations and is not susceptible to over-counting artifacts related to fluorescent dye re-blinking (Stone et al., 2017). Auto-correlation analysis of CD3 protein was performed using MATLAB software provided by Sarah Shelby and Sarah Veatch from University of Michigan. Regions containing cells were masked by a region of interest, positions. Only localizations with photon count > 400 photons were included, and localizations that appeared within one pixel in five consecutive frames were merged together and fitted as one localization. The final images were rendered by representing the x and y positions of the localizations as a Gaussian with a width that corresponds to the determined localization precision. Sample drift during acquisition was calculated and subtracted by reconstructing dSTORM images from subsets of frames (500 frames) and correlating these images to a reference frame (the initial time segment).

DBSCAN cluster analysis
Quantitative cluster analysis was based on Density-based spatial clustering of applications with noise (DBSCAN) (Ester et al., 1996). The DBSCAN method detects clusters using a propagative method which links proteins belonging to the same cluster based on the minimum number of neighbors ε (ε = 7) in the radius r (r = 25 nm). Clus-DoC (Pageon et al., 2016) MATLAB based software with implemented DBSCAN analysis was used. The x and y coordinate list of dSTORM localizations was used and regions containing cells were selected to give the mean ± SD value of CD3 cluster size per cell.

Fluorescent Recovery after Photobleaching (FRAP) and analysis
Prior to FRAP experiment, cells were incubated for 20 minutes at 37 °C with an anti-CD3 primary antibody directly conjugated with Alexa Fluor 647 (BioLegend). Cells were washed with cell media and seeded on glass µ-slide 8 well chamber (Ibidi) coated with Poly-L-Lysine for 5 min before imaging. Cysteamine based dSTORM imaging buffer was used to perform the
Atomistic Molecular Dynamics Simulations

The transmembrane region (TMR) of the T cell receptor (TCR) was extracted from the cryo-EM structure PDB: 6JXR (Dong et al., 2019) and used for atomistic molecular dynamics simulations. The residues of TCR TMR are numbered according to that used in our experiments (“n - 1” compared to PDB: 6JXR, i.e., our i1Y291 is j1Y292 in 6JXR). The TMR sequences used are shown in Table S3. The octameric protein structure was inserted in a complex asymmetric bilayer (lipid concentration is shown in Table S4) using CHARMM-GUI (https://charmm-gui.org) and was solvated with TIP3 water molecules. The lipid types and their concentrations in our simulated bilayer were considered from studies on the T cell membrane conducted by Zech et al. (2009). The system was then neutralized with a concentration of 150 mM of NaCl ions. The resultant molecular system and molecular dynamics parameters were obtained from CHARMM-GUI and thereafter run using Gromacs 2016.4 (Van Der Spoel et al., 2005) using the CHARMM36 forcefield (Lee et al., 2016). An energy-minimization of the entire system was conducted for 5000 steps using the steepest descent algorithm. The fully equilibrated system was used to generate starting points for 3 production simulation repeats with different initial velocities. This was done for the wild-type complex, Tα38, Tα41 and βιA291 mutants which started from the same initial configuration. Each production simulation run was for 1250 ns employing a 2 femtoseconds time-step and the co-ordinates were saved every 40 picoseconds. The Nose-Hoover thermostat (Hoover, 1985) was used with a reference temperature of 323 K and coupling constant of 1 picosecond. The Parrinello-Rahman thermostat (Parrinello and Rahman, 1981) was used with a semi-isotropic pressure coupling type, reference pressure of 1 atmosphere, compressibility value of 4.5 x 10^{-5} bar^{-1} and coupling constant of 5 picoseconds. The Particle mesh Ewald algorithm (Essmann et al., 1995) with a 12 Å distance cut-off was used to define non-bonded van der Waals (Lennard-Jones) and coulombic interactions. Visualization was carried out using VMD (Humphrey et al., 1996). Protein-protein interaction profiles and spatial distribution plots are a result of merged data from all the 3 repeats of all-atom simulations. To calculate the spatial distribution of \( \zeta \) relative to \( \alpha \beta \), the positions of C\(_{\alpha}\) atoms of \( \alpha \beta \) were fixed throughout the simulation time. The spatial distributions of C\(_{\alpha}\) atoms of \( \zeta \) and \( \alpha \beta \) are viewed from the extracellular region.

Modeling of the 1G4 TCR affinity mutants

The 1G4-A2-SLL structure (from PDB: 2BNR) (Chen et al., 2005) was used to model the 1G4 QM-\( \omega \)-A2-SLL and 1G4 wtc51-A2-SLL tri-molecular complex structures. Sequences were adjusted with COOT (Emsley and Cowtan, 2004) and graphical representations and analysis were prepared with PYMOL (Delano, 2002; Available: https://pymol.org/2/).

QUANTIFICATION AND STATISTICAL ANALYSIS

Flow cytometry

All experiments were replicated at least two - three times with technical and/or biological replicates each time. Raw data was processed in FlowJo (FlowJo software, part of BD) and MFIs, counts or percentages were extracted from FlowJo as excel files. Statistical analysis and non-linear regression fitting were performed with Prism (GraphPad Software). Significance was assessed by two-tailed paired or unpaired t test. Non-linear regressions were tested for Goodness of Fit (R\(^2\)), for normality (D’Agostino & Pearson omnibus normality test) and with the replicates test. Non-linear regression fits are specified in the methods paragraph describing the experimental procedure. R\(^2\) and p-value for the fits, significance tests and significance are indicated in the figure or figure legend.

Pull-down and Immunoblotting

Experiments were replicated at least two - three times with technical and/or biological replicates each time as indicated at the representing figure. Raw data was extracted from Image studio (LI-COR Biosciences) and processed in Excel and Prism (GraphPad Software). Statistical analysis (two-tailed unpaired t test) was performed and method and significance are indicated in the figure or figure legend.

Microscopy

Samples were tested for normality with a Kolmogorov–Smirnov test. The statistical significance of differences between two datasets was assessed by a two-tailed t test assuming unequal variance. All statistical analysis was performed using Origin software (OriginPro 2017; OriginLab).
Simulations
For the atomistic simulations multiple repeat simulations were performed to ensure reproducibility of our results. Analyses of the simulations were conducted using Gromacs, VMD, and locally written code.

Modeling
Graphics and analysis were prepared with PYMOL (DeLano, 2002; Available: https://pymol.org/2/).

Significance
* p ≤ 0.05 /** p ≤ 0.01/*** p ≤ 0.001/**** p ≤ 0.0001/ ns = not significant.